222. 一次性ネフローゼ症候群
［臨床試験数：234，薬物数：241（DrugBank：78），標的遺伝子数：59，標的パスウェイ数：185］
Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04573920 (ClinicalTrials.gov) | February 1, 2021 | 28/9/2020 | Atrasentan in Patients With Proteinuric Glomerular Diseases | A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases | IgA Nephropathy;Focal Segmental Glomerulosclerosis;Alport Syndrome;Diabetic Kidney Disease;Diabetic Nephropathy Type 2;Immunoglobulin A Nephropathy | Drug: Atrasentan | Chinook Therapeutics U.S., Inc. | NULL | Not yet recruiting | 18 Years | N/A | All | 80 | Phase 2 | NULL |
| 2 | NCT04652570 (ClinicalTrials.gov) | February 2021 | 23/11/2020 | Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy | A Phase 1b/2a Study of VB119 in Adult Subjects With Primary Membranous Nephropathy | Membranous Nephropathy | Drug: VB119 | ValenzaBio, Inc. | NULL | Not yet recruiting | 18 Years | N/A | All | 30 | Phase 1;Phase 2 | NULL |
| 3 | NCT04629248 (ClinicalTrials.gov) | December 31, 2020 | 27/10/2020 | A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy | A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy | Primary Membranous Nephropathy | Drug: Obinutuzumab;Drug: Tacrolimus;Drug: Methylprednisolone;Drug: Acetaminophen;Drug: Diphenhydramine | Hoffmann-La Roche | NULL | Not yet recruiting | 18 Years | 75 Years | All | 140 | Phase 3 | United States;Argentina;Brazil;China;Israel;Italy;Poland |
| 4 | ChiCTR2000037467 | 2020-12-31 | 2020-08-28 | Effect of Tripterygium wilfordii polyglycoside tablets on the inhibition of TM on complement pathway and related inflammatory markers in membranous nephropathy | The complement pathway and related inflammatory factor markers in the treatment of idiopathic membranous nephropathy | idiopathic membranous nephropathy | Gold Standard:Cell hemolysis test;Index test:Immunochemiluminescence (ECL) and flow cytometry (FCM) were used to determine the activity of each complement pathway and the target of complement; Complement hemolysis test is usually used to determine the activity of total complement and single complement component, but it is difficult to be applied to clinical ; | Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine | NULL | Pending | 18 | 80 | Both | Target condition:40;Difficult condition:40 | China | |
| 5 | EUCTR2020-002637-15-GB (EUCTR) | 22/12/2020 | 23/10/2020 | Phase 2, multicenter, open-label, randomized, controlled study is designed to evaluate the safety and efficacy of APL-2 in patients who have post-transplant recurrence of C3G or IC-MPGN | AN OPEN-LABEL, RANDOMIZED, CONTROLLED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PEGCETACOPLAN IN THE TREATMENT OF POST-TRANSPLANT RECURRENCE OF C3G OR IC-MPGN - NOBLE | complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN);Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan | Apellis Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 12 | Phase 2 | United States;France;Argentina;Spain;Brazil;Austria;Australia;Netherlands;Switzerland;Italy;United Kingdom | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2020-002985-15-DE (EUCTR) | 21/12/2020 | 31/08/2020 | Open-label, 2-arm, multicenter clinical trial to assess safety, efficacy and PK/PD of MOR202 in anti-PLA2R antibody positive membranous nephropathy (aMN) | A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (NewPLACE) - NewPLACE | Anti-PLA2R antibody positive membranous nephropathy (aMN) MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: MOR202 INN or Proposed INN: not yet assigned Other descriptive name: MOR03087 | MorphoSys AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 22 | Phase 2 | Taiwan;Greece;Australia;Russian Federation;Georgia;Germany;United Kingdom;Korea, Republic of | ||
| 7 | NCT04278729 (ClinicalTrials.gov) | December 2020 | 18/2/2020 | A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome | A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome | Nephrotic Syndrome;Membranous Nephropathy | Drug: Apixaban 5 MG | University of North Carolina, Chapel Hill | American College of Clinical Pharmacy | Not yet recruiting | 18 Years | 79 Years | All | 30 | Phase 1 | United States |
| 8 | EUCTR2019-003607-35-SK (EUCTR) | 12/11/2020 | 09/10/2020 | A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS) | A PHASE 2, 12-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) | Focal Segmental Glomerulosclerosis (FSGS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12] | Product Name: PF-06730512 Product Code: PF-06730512 INN or Proposed INN: PF-06730512 Other descriptive name: PF-06730512 | Pfizer Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 44 | Phase 2 | United States;Czechia;Slovakia;Spain;Thailand;Italy;United Kingdom;France;Canada;Poland;Romania;Germany;Japan | ||
| 9 | NCT04572854 (ClinicalTrials.gov) | November 2020 | 29/9/2020 | Phase II Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN | An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN | C3G;IC-MPGN;Renal Transplant | Drug: Pegcetacoplan | Apellis Pharmaceuticals, Inc. | NULL | Not yet recruiting | 18 Years | N/A | All | 12 | Phase 2 | NULL |
| 10 | NCT02399462 (ClinicalTrials.gov) | November 2020 | 8/1/2015 | Acthar for Treatment of Post-transplant FSGS | Acthar for Treatment of Post-transplant FSGS | FSGS;Renal Transplantation;Kidney Transplantation | Drug: Acthar | University of North Carolina, Chapel Hill | Mallinckrodt | Not yet recruiting | 18 Years | N/A | All | 20 | Phase 4 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2019-003607-35-DE (EUCTR) | 26/10/2020 | 02/10/2020 | A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS) | PHASE 2, 12-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) | Focal Segmental Glomerulosclerosis (FSGS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12] | Product Name: PF-06730512 Product Code: PF-06730512 INN or Proposed INN: PF-06730512 Other descriptive name: PF-06730512 | Pfizer Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 44 | Phase 2 | United States;Slovakia;Spain;Thailand;Italy;United Kingdom;France;Czech Republic;Canada;Poland;Romania;Germany;Japan | ||
| 12 | EUCTR2019-003607-35-PL (EUCTR) | 23/10/2020 | 20/10/2020 | A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS) | A PHASE 2, 12-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) | Focal Segmental Glomerulosclerosis (FSGS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12] | Product Name: PF-06730512 Product Code: PF-06730512 INN or Proposed INN: PF-06730512 Other descriptive name: PF-06730512 | Pfizer Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 44 | Phase 2 | United States;France;Czech Republic;Canada;Thailand;Spain;Poland;Romania;Germany;United Kingdom;Japan;Italy | ||
| 13 | EUCTR2020-002985-15-GR (EUCTR) | 22/10/2020 | 11/09/2020 | Open-label, 2-arm, multicenter clinical trial to assess safety, efficacy and PK/PD of MOR202 in anti-PLA2R antibody positive membranous nephropathy (aMN) | A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (NewPLACE) - NewPLACE | Anti-PLA2R antibody positive membranous nephropathy (aMN) MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: MOR202 INN or Proposed INN: not yet assigned Other descriptive name: MOR03087 | MorphoSys AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 22 | Phase 2 | Taiwan;Greece;Australia;Russian Federation;Georgia;Germany;United Kingdom;Korea, Republic of | ||
| 14 | EUCTR2020-002985-15-GB (EUCTR) | 12/10/2020 | 25/08/2020 | Open-label, 2-arm, multicenter clinical trial to assess safety, efficacy and PK/PD of MOR202 in anti-PLA2R antibody positive membranous nephropathy (aMN) | A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (NewPLACE) - NewPLACE | Anti-PLA2R antibody positive membranous nephropathy (aMN) MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: MOR202 INN or Proposed INN: not yet assigned Other descriptive name: MOR03087 | MorphoSys AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 22 | Phase 2 | Taiwan;Greece;Australia;Russian Federation;Georgia;Germany;United Kingdom;Korea, Republic of | ||
| 15 | ChiCTR2000037014 | 2020-10-01 | 2020-08-26 | The predictive value of gut permeability in children with steroid dependent nephrotic syndrome | The predictive value of gut permeability in children with steroid dependent nephrotic syndrome | Primary nephrotic syndrome | Steroid sensitive nephrotic syndrome group (SSNS group):Prednisone treatment recommended by the guidelines;Steroid dependent nephrotic syndrome group (SDNS group):Prednisone treatment recommended by the guidelines; | Shanghai Children's Hospital | NULL | Pending | Both | Steroid sensitive nephrotic syndrome group (SSNS group):40;Steroid dependent nephrotic syndrome group (SDNS group):30; | China | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT04183101 (ClinicalTrials.gov) | October 1, 2020 | 14/11/2019 | Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy | Phase 2, Multicenter, Randomized, Open-label, Controlled, 2-arm Cross-over Study to Evaluate the Clinical Efficacy of a Renin Inhibitor, Aliskiren, Compared to an Angiotensin Converting Enzyme Inhibitor, Enalapril, in C3 Glomerulopathy | C3 Glomerulopathy;Membranoproliferative Glomerulonephritis;Complement Abnormality;Dense Deposit Disease;C3 Glomerulonephritis | Drug: Aliskiren;Drug: Enalapril | Region Skane | NULL | Recruiting | 6 Years | N/A | All | 30 | Phase 2 | Sweden |
| 17 | ChiCTR2000038353 | 2020-09-30 | 2020-09-21 | Effect of levothyroxine on the prognosis of children with PNS | Effect of levothyroxine on the prognosis of children with PNS | Primary nephrotic syndrome | trial group:NS basic treatment + LT4 replacement therapy;control group:after NS basic treatment for 3 weeks, LT4 replacement therapy was started; | Chidren's Hospital Affiliated to Capital Institute of Pediatrics, Beijing, China | NULL | Recruiting | 1 | 16 | Both | trial group:90;control group:90; | China | |
| 18 | ChiCTR2000032422 | 2020-09-01 | 2020-04-27 | The efficacy and safety of tacrolimus monotherapy in the treatment of idiopathic membranous nephropathy: an open, prospective, real-world study | The efficacy and safety of tacrolimus monotherapy in the treatment of idiopathic membranous nephropathy: an open, prospective, real-world study | Idiopathic membranous nephropathy | experimental group:Tacrolimus;control group:conservative treatment; | Shenzhen Second People's Hospital | NULL | Pending | Both | experimental group:24;control group:24; | Phase 4 | Chiina | ||
| 19 | NCT04456816 (ClinicalTrials.gov) | August 31, 2020 | 24/6/2020 | A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN | An Exploratory, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AP1189 Versus Placebo Administered for 4 Weeks as an add-on to Patients, in ACE Inhibitor or Angiotensin II Receptor Blocker Treatment, With Idiopathic Membranous Nephropathy | Idiopathic Membranous Nephropathy | Drug: 100 mg AP1189;Drug: Placebo | SynAct Pharma Aps | NULL | Recruiting | 18 Years | 85 Years | All | 23 | Phase 2 | Denmark |
| 20 | EUCTR2019-001212-29-DK (EUCTR) | 13/08/2020 | 09/06/2020 | Causes and prevention of thrombosis developed due to the kidney disease nephrotic syndrome | Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome | Nephrotic syndrome is defined as severe proteinuria (> 0.5 g / day), edema and hypoalbuminemia. It is conditioned by a defect in the kidney's glomerular filtration barrier, resulting in the loss of a large number of plasma proteins including coagulation factors and consequently a increased risk of thromboembolic complications. The most frequent cause of nephrotic syndrome is the renal disease membranous nephropathy, which is associated with the greatest risk of thromboembolic complications. MedDRA version: 21.1;Level: LLT;Classification code 10029167;Term: Nephrotic syndrome with lesion of membranous glomerulonephritis;System Organ Class: 100000004857 MedDRA version: 20.0;Classification code 10029165;Term: Nephrotic syndrome in diseases classified elsewhere;System Organ Class: 100000004857;Therapeutic area: Not possible to specify | Trade Name: Fragmin INN or Proposed INN: Dalteparin Other descriptive name: Dalteparin Trade Name: Eliquis INN or Proposed INN: Apixaban Other descriptive name: Apixaban | Aarhus University Hospital, Henrik Birn | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Phase 1;Phase 2 | Denmark | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT04498962 (ClinicalTrials.gov) | August 2020 | 21/7/2020 | The Effect of Danzhu Fuyuan Granule as Adjunctive Therapy for Chronic Stable Angina, Vascular Dementia and Idiopathic Membranous Nephropathy: A Bayesian Basket Trial | The Effect of Danzhu Fuyuan Granule as Adjunctive Therapy for Chronic Stable Angina, Vascular Dementia and Idiopathic Membranous Nephropathy: A Bayesian Basket Trial | Chronic Stable Angina;Vascular Dementia;Idiopathic Membranous Nephropathy | Drug: Danzhu Fuyuan Granule | Jingqing Hu | NULL | Not yet recruiting | 18 Years | 70 Years | All | 240 | N/A | China |
| 22 | NCT04387448 (ClinicalTrials.gov) | July 28, 2020 | 11/5/2020 | A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease | A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease | Kidney Diseases;Diabetic Nephropathies;Glomerulosclerosis, Focal Segmental;Nephrosis, Lipoid;Urologic Diseases;Diabetes Complications;Diabetes Mellitus;Endocrine System Diseases;Glomerulonephritis;Nephritis;Nephrosis | Drug: GFB-887;Drug: Placebo | Goldfinch Bio, Inc. | NULL | Recruiting | 18 Years | 75 Years | All | 125 | Phase 2 | United States |
| 23 | ChiCTR2000033766 | 2020-07-01 | 2020-06-11 | Diagnostic value of serum C4d, PLA2R, THSD7A antibody in idiopathic membranous nephropathy and analysis of therapeutic effect of tacrolimus | Diagnostic value of serum C4d, PLA2R, THSD7A antibody in idiopathic membranous nephropathy and analysis of therapeutic effect of tacrolimus | Membranous nephropathy | 1:Prednisone + cyclophosphamide;2:Prednisone + Tacrolimus; | The First Affiliated Hospital of Bengbu Medical College | NULL | Pending | 17 | 70 | Both | 1:30;2:30; | Phase 4 | China |
| 24 | EUCTR2020-000185-42-FR (EUCTR) | 12/06/2020 | 26/05/2020 | Phase 2a Study of VX 147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis. | A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis. | APOL1-mediated Focal segmental glomerulosclerosis (FSGS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] | Product Name: VX-147 Product Code: VX-147 INN or Proposed INN: VX147 Other descriptive name: VX-147 | Vertex Pharmaceuticals Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 2 | United States;France;United Kingdom | ||
| 25 | NCT04340362 (ClinicalTrials.gov) | June 8, 2020 | 7/4/2020 | Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis | A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis | Glomerulosclerosis, Focal Segmental | Drug: VX-147 | Vertex Pharmaceuticals Incorporated | NULL | Recruiting | 18 Years | 65 Years | All | 10 | Phase 2 | United States;France;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | ChiCTR2000033540 | 2020-06-01 | 2020-06-04 | Prospective Randomized Trial on Efficacy of Rituximab Combined Therapy and Supportive Therapy on Early-Stage Non-Nephrotic Primary Membranous Nephropathy | Prospective Randomized Trial on Efficacy of Rituximab Combined Therapy and Supportive Therapy on Early-Stage Non-Nephrotic Primary Membranous Nephropathy | Membranous Nephropathy | experimental group:Rituximab 600mg iv, and supportive treatment;control group:Supportive treatment according to KDIGO guideline; | Peking Union Medical College Hospital, Chinese Academy of Medical Sciences | NULL | Recruiting | 18 | 70 | Both | experimental group:19;control group:19; | Phase 4 | China |
| 27 | EUCTR2020-000185-42-GB (EUCTR) | 01/06/2020 | 23/03/2020 | Phase 2a Study of VX 147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis. | A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis. | APOL1-mediated Focal segmental glomerulosclerosis (FSGS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] | Product Name: VX-147 Product Code: VX-147 INN or Proposed INN: VX147 Other descriptive name: VX-147 | Vertex Pharmaceuticals Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 2 | France;United States;United Kingdom | ||
| 28 | ChiCTR2000032523 | 2020-06-01 | 2020-05-01 | Efficacy and safety of rituximab in the treatment of primary membranous nephropathy with type 2 diabetes mellitus: a single-center randomized controlled trial. | Efficacy and safety of rituximab in the treatment of primary membranous nephropathy with type 2 diabetes mellitus: a single-center randomized controlled trial | membranous nephropathy | experimental group:rituximab;control group:tacrolimus; | Xinqiao Hospital | NULL | Pending | 18 | 80 | Both | experimental group:40;control group:40; | Phase 4 | China |
| 29 | NCT04424862 (ClinicalTrials.gov) | June 2020 | 7/6/2020 | Multitarget Therapy for Idiopathic Membranous Nephropathy | Multitarget Therapy for Idiopathic Membranous Nephropathy | Efficacy | Drug: Prednisone, ciclosporin and mycophenolate mofetil;Drug: Ponticelli Regimen | Beijing Friendship Hospital | NULL | Not yet recruiting | 18 Years | 70 Years | All | 78 | Phase 4 | China |
| 30 | EUCTR2020-000971-18-DK (EUCTR) | 28/05/2020 | 04/04/2020 | A double-blind study for patients with idiopathic membranous nephropathy in treatment with ACE inhibor or angiotensin II receptor blockers. The trial will take place in hospitals in Denmark and Belgium. To better assess the mechanism of action of AP1189, the compound is compared to an inactive substance (placebo).The purpose of the trial is to investigate the safety of the new drug, its tolerability, uptake, metabolism, distribution, and excretion in the body (pharmacokinetics) and its effect | An exploratory, randomized, double-blind, multicenter, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and efficacy of AP1189 daily doses versus placebo administered for 4 weeks as an add-on to patients, in ACE inhibitor or angiotensin II receptor blocker treatment, with idiopathic membranous nephropathy - SynAct-CS003 | Idiopathic membranous nephropathy MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 21.1;Level: PT;Classification code 10029164;Term: Nephrotic syndrome;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: AP1189 INN or Proposed INN: Not applicable | SynAct Pharma ApS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 18 | Phase 2 | Denmark | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | EUCTR2019-001734-34-NL (EUCTR) | 07/04/2020 | 22/08/2019 | Efficacy and safety of LNP023 compared with rituximab in subjects with idiopathic membranous nephropathy. | A randomized, treatment open-label, dose-blinded, parallel group, three arm, proof-of-concept clinical trial to investigate the efficacy and safety of LNP023 compared with rituximab in the treatment of subjects with idiopathic membranous nephropathy. | Idiopathic Membranous nephropathy MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: LNP023 INN or Proposed INN: not yet established Other descriptive name: LNP023 HYDROCHLORIDE SALT Product Code: LNP023 INN or Proposed INN: not yet established Other descriptive name: LNP023 HYDROCHLORIDE SALT Product Code: LNP023 INN or Proposed INN: not yet established Other descriptive name: LNP023 HYDROCHLORIDE SALT Trade Name: MabThera 500 mg concentrate for solution for infusion INN or Proposed INN: RITUXIMAB Trade Name: MabThera 100 mg concentrate for solution for infusion INN or Proposed INN: RITUXIMAB | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 72 | Phase 2 | France;United States;Czech Republic;Argentina;Spain;Singapore;Russian Federation;Germany;Netherlands;United Kingdom;India | ||
| 32 | ChiCTR2000031003 | 2020-03-25 | 2020-03-20 | Study and promotion of FSGS treatment based on low concentration tacrolimus optimized immunosuppressive regimen | Study and promotion of FSGS treatment based on low concentration tacrolimus optimized immunosuppressive regimen | Idiopathic focal segmental glomerulosclerosis | Tacrolimus group:Low dose of tacrolimus combined with hormone;hormone group:Use hormones; | Southwest Hospital, the First Affiliated Hospital of Army Medical University | NULL | Recruiting | Both | Tacrolimus group:19;hormone group:19; | Phase 4 | China | ||
| 33 | NCT03970577 (ClinicalTrials.gov) | January 14, 2020 | 15/4/2019 | RItuximab From the FIRst Episode of Idiopathic Nephrotic Syndrome | Rituximab From the First Episode of Minimal Change Nephrotic Syndrome for Preventing Relapse Risk in Adult Patients: a Multicenter Randomized Controlled Trial | Minimal Change Nephrotic Syndrome (MCNS) | Drug: Rituximab;Drug: Prednisone | Assistance Publique - Hôpitaux de Paris | NULL | Active, not recruiting | 18 Years | N/A | All | 148 | Phase 2 | France |
| 34 | NCT03804359 (ClinicalTrials.gov) | January 14, 2020 | 11/1/2019 | Personalized Medicine for Membranous Nephropathy | Personalized Medicine for Membranous Nephropathy | Idiopathic Membranous Nephropathy | Drug: Rituximab | Centre Hospitalier Universitaire de Nice | NULL | Recruiting | 18 Years | N/A | All | 64 | Phase 2 | France |
| 35 | NCT04065438 (ClinicalTrials.gov) | January 1, 2020 | 20/8/2019 | Post Approval Study for Treatment of Drug-resistant Adult Primary FSGS Using the LIPOSORBER® LA-15 System | Treatment of Drug-resistant Adult Primary Focal Segmental Glomerulosclerosis and Post -Transplant Recurrence Using the LIPOSORBER® LA-15 System | Focal Segmental Glomerulosclerosis | Device: LIPOSORBER® LA-15 | Kaneka Pharma America LLC | NULL | Recruiting | 22 Years | 75 Years | All | 35 | N/A | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT03949855 (ClinicalTrials.gov) | December 18, 2019 | 13/5/2019 | Belimumab With Rituximab for Primary Membranous Nephropathy | Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI) | Membranous Nephropathy;MN | Drug: Belimumab;Drug: Placebo for Belimumab;Drug: Rituximab | National Institute of Allergy and Infectious Diseases (NIAID) | Immune Tolerance Network (ITN);GlaxoSmithKline | Recruiting | 18 Years | 75 Years | All | 124 | Phase 2 | United States;Canada |
| 37 | NCT04154787 (ClinicalTrials.gov) | November 23, 2019 | 8/10/2019 | Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy | A Randomized, Treatment Open-label, Dose-blinded Parallel Group, Three Arm, Proof-of-concept Clinical Trial to Investigate the Efficacy and Safety of LNP023 Compared With Rituximab in the Treatment of Subjects With Idiopathic Membranous Nephropathy | Glomerulonephritis, Membranous | Drug: LNP023;Drug: Rituximab | Novartis Pharmaceuticals | NULL | Recruiting | 18 Years | N/A | All | 72 | Phase 2 | Argentina;Czechia;France;Germany;India;Netherlands;Singapore;Spain;United Kingdom |
| 38 | EUCTR2019-001734-34-ES (EUCTR) | 12/11/2019 | 04/09/2019 | Efficacy and safety of LNP023 compared with rituximab in subjects with idiopathic membranous nephropathy. | A randomized, treatment open-label, dose-blinded, parallel group, three arm, proof-of-concept clinical trial to investigate the efficacy and safety of LNP023 compared with rituximab in the treatment of subjects with idiopathic membranous nephropathy. | Idiopathic Membranous nephropathy MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Novartis Farmacéutica, S.A. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 72 | Phase 2 | France;United States;Czech Republic;Argentina;Spain;Singapore;Russian Federation;Netherlands;Germany;United Kingdom;India | |||
| 39 | ChiCTR1900027128 | 2019-10-30 | 2019-11-01 | Validation of Anti-Phospholipase A2 Receptor Antibody ELISA in a Chinese Cohort With Idiopathic Membranous Nephropathy: a Multicenter Observational Study | The Cut-off Value of Anti-Phospholipase A2 Receptor Antibody ELISA in Chinese Patients | Membranous Nephrology | Gold Standard:Pathological diagnosis according to kidney biopsy(Chapter 7, 7.1 Evaluation of MN, KDIGO 2012);Index test:Serum PLA2R Antibody by ELISA; | Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University | NULL | Recruiting | Both | Target condition:288;Difficult condition:290 | N/A | China | ||
| 40 | EUCTR2019-000780-24-ES (EUCTR) | 25/10/2019 | 26/07/2019 | Open Label Clinical Trial to assess Safety and Efficacy of MOR202 in Membranous Nephropathy | A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in anti-PLA2R antibody positive Membranous Nephropathy (aMN) - M-PLACE | Primary (anti-PLA2R antibody positive) Membranous Nephropathy MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: MOR202 Product Code: MOR202 INN or Proposed INN: No INN assigned yet Other descriptive name: MOR03087 | MorphoSys AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 1;Phase 2 | France;United States;European Union;Spain;Netherlands | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | EUCTR2019-001734-34-FR (EUCTR) | 23/10/2019 | 13/09/2019 | Efficacy and safety of LNP023 compared with rituximab in subjects with idiopathic membranous nephropathy. | A randomized, treatment open-label, dose-blinded, parallel group, three arm, proof-of-concept clinical trial to investigate the efficacy and safety of LNP023 compared with rituximab in the treatment of subjects with idiopathic membranous nephropathy. | Idiopathic Membranous nephropathy MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 72 | Phase 2 | United States;France;Czech Republic;Argentina;Spain;Singapore;Russian Federation;Netherlands;Germany;United Kingdom;India | |||
| 42 | NCT04145440 (ClinicalTrials.gov) | October 15, 2019 | 18/10/2019 | Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) | A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (aMN) | Glomerulonephritis, Membranous;antiPLA2R Positive | Drug: MOR202 | MorphoSys AG | NULL | Recruiting | 18 Years | 80 Years | All | 30 | Phase 1;Phase 2 | United States;Belgium;France;Italy;Netherlands;Spain |
| 43 | EUCTR2017-003022-32-PL (EUCTR) | 12/10/2019 | 20/08/2019 | An open, dose escalation study in patients with Primary Focal Segmental Glomerulosclerosis (FSGS - a type of glomerular disease causes scarring in the kidney) and Nephrotic Syndrom (collection of symptoms due to kidney damage) | An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome | Primary Focal Segmental Glomerulosclerosis (FSGS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: CCX140-B INN or Proposed INN: not available yet | ChemoCentryx, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 13 | Phase 2 | United States;France;Canada;Poland;United Kingdom | ||
| 44 | EUCTR2019-000780-24-IT (EUCTR) | 08/10/2019 | 22/01/2020 | Open Label Clinical Trial to assess Safety and Efficacy of MOR202 in Membranous Nephropathy | A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in anti-PLA2R antibody positive Membranous Nephropathy (aMN) - M-PLACE | Primary (anti-PLA2R antibody positive) Membranous Nephropathy MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: MOR202 Product Code: MOR202 INN or Proposed INN: No INN assigned yet Other descriptive name: MOR03087 | MorphoSys AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 1;Phase 2 | France;United States;European Union;Spain;Netherlands;Italy | ||
| 45 | NCT04009668 (ClinicalTrials.gov) | October 2, 2019 | 2/7/2019 | Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease | Precision Medicine Proof of Concept for Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease | FSGS;MCD;Focal Segmental Glomerulosclerosis;Minimal Change Disease | Drug: adalimumab | University of Michigan | New York University | Recruiting | 6 Years | 70 Years | All | 8 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | JPRN-UMIN000038242 | 2019/10/01 | 09/10/2019 | The effect of Evolocumab on primary nephrotic syndrome | The effect of Evolocumab on primary nephrotic syndrome - The effect of Evolocumab on primary nephrotic syndrome | Primary nephrotic syndrome | Evolocumab | Department of Nephrology, Nippon Medical School | NULL | Recruiting | 16years-old | Not applicable | Male and Female | 10 | Not selected | Japan |
| 47 | EUCTR2019-000780-24-NL (EUCTR) | 24/09/2019 | 03/07/2019 | Open Label Clinical Trial to assess Safety and Efficacy of MOR202 in Membranous Nephropathy | A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in anti-PLA2R antibody positive Membranous Nephropathy (aMN) - M-PLACE - M-PLACE | Primary (anti-PLA2R antibody positive) Membranous Nephropathy MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: MOR202 Product Code: MOR202 INN or Proposed INN: No INN assigned yet Other descriptive name: MOR03087 | MorphoSys AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 1;Phase 2 | France;United States;European Union;Spain;Australia;Netherlands;Italy;Korea, Republic of | ||
| 48 | EUCTR2019-000780-24-FR (EUCTR) | 23/09/2019 | 15/10/2019 | Open Label Clinical Trial to assess Safety and Efficacy of MOR202 in Membranous Nephropathy | A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in anti-PLA2R antibody positive Membranous Nephropathy (aMN) - M-PLACE | Primary (anti-PLA2R antibody positive) Membranous Nephropathy MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857 ;Therapeutic area: Body processes [G] - Immune system processes [G12] | MorphoSys AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 1;Phase 2 | United States;France;European Union;Spain;Netherlands | |||
| 49 | EUCTR2016-005141-23-PT (EUCTR) | 23/09/2019 | 12/04/2019 | Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) | A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) | Focal segmental glomerulosclerosis (FSGS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Sparsentan Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: SPARSENTAN Trade Name: Irbesartan tablets Product Name: over-encapsulated Irbesartan Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN Trade Name: Irbesartan tablets Product Name: over-encapsulated Irbesartan Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN | Retrophin, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 300 | Phase 3 | United States;Portugal;Taiwan;Estonia;Hong Kong;Spain;United Kingdom;Italy;France;Hungary;Czech Republic;Canada;Argentina;Poland;Belgium;Brazil;Croatia;Australia;Denmark;Germany;New Zealand;Sweden;Korea, Republic of | ||
| 50 | EUCTR2019-001734-34-GB (EUCTR) | 23/09/2019 | 07/08/2019 | Efficacy and safety of LNP023 compared with rituximab in subjects with idiopathic membranous nephropathy. | A randomized, treatment open-label, dose-blinded, parallel group, three arm, proof-of-concept clinical trial to investigate the efficacy and safety of LNP023 compared with rituximab in the treatment of subjects with idiopathic membranous nephropathy. | Idiopathic Membranous nephropathy MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: LNP023 INN or Proposed INN: not yet established Other descriptive name: LNP023 HYDROCHLORIDE SALT Product Code: LNP023 INN or Proposed INN: not yet established Other descriptive name: LNP023 HYDROCHLORIDE SALT Product Code: LNP023 INN or Proposed INN: not yet established Other descriptive name: LNP023 HYDROCHLORIDE SALT Trade Name: MabThera 500 mg concentrate for solution for infusion INN or Proposed INN: RITUXIMAB Trade Name: MabThera 100 mg concentrate for solution for infusion INN or Proposed INN: RITUXIMAB | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 72 | Phase 2 | United States;France;Czech Republic;Argentina;Spain;Singapore;Russian Federation;Netherlands;Germany;United Kingdom;India | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | EUCTR2016-005141-23-SE (EUCTR) | 31/07/2019 | 28/03/2019 | Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) | A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) | Focal segmental glomerulosclerosis (FSGS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Sparsentan/Over-encapsulated Sparsentan tablets Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: SPARSENTAN Trade Name: Irbesartan tablets Product Name: over-encapsulated Irbesartan Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN Trade Name: Irbesartan tablets Product Name: over-encapsulated Irbesartan Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN Product Name: Sparsentan Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: SPARSENTAN | Retrophin, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 300 | Phase 3 | United States;Portugal;Taiwan;Estonia;Hong Kong;Spain;United Kingdom;Italy;France;Hungary;Czech Republic;Canada;Argentina;Poland;Belgium;Brazil;Croatia;Australia;Denmark;Germany;New Zealand;Korea, Republic of;Sweden | ||
| 52 | EUCTR2016-005141-23-HR (EUCTR) | 25/07/2019 | 11/10/2019 | Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) | A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) | Focal segmental glomerulosclerosis (FSGS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Sparsentan Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: SPARSENTAN Trade Name: Irbesartan tablets Product Name: over-encapsulated Irbesartan Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN Trade Name: Irbesartan tablets Product Name: over-encapsulated Irbesartan Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN | Retrophin, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 300 | Phase 3 | Portugal;United States;Hong Kong;Estonia;Taiwan;Spain;Italy;United Kingdom;France;Hungary;Czech Republic;Canada;Argentina;Poland;Belgium;Brazil;Croatia;Australia;Denmark;Germany;New Zealand;Korea, Republic of;Sweden | ||
| 53 | EUCTR2016-005141-23-BE (EUCTR) | 15/07/2019 | 14/05/2019 | Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) | A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) | Focal segmental glomerulosclerosis (FSGS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Sparsentan Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: SPARSENTAN Trade Name: Irbesartan tablets Product Name: over-encapsulated Irbesartan Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN Trade Name: Irbesartan tablets Product Name: over-encapsulated Irbesartan Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN | Retrophin, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 300 | Phase 3 | United States;Portugal;Taiwan;Estonia;Hong Kong;Spain;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Argentina;Poland;Belgium;Brazil;Croatia;Australia;Denmark;Germany;New Zealand;Sweden;Korea, Republic of | ||
| 54 | NCT03763643 (ClinicalTrials.gov) | July 1, 2019 | 7/8/2018 | PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant | PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant | Focal Segmental Glomerulosclerosis | Drug: Rituximab;Drug: Placebo;Procedure: Plasmapheresis | University of Minnesota | United States Department of Defense | Recruiting | 1 Year | 40 Years | All | 160 | Phase 1;Phase 2 | United States |
| 55 | EUCTR2018-004611-50-GB (EUCTR) | 14/06/2019 | 11/04/2019 | The Use of Rituximab IN treatment of immune-mediated Glomerulonephritis (TURING) | A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING) - TURING | Minimal Change Disease (MCD) and Focal segmental glomerulosclerosis (FSGS) | Cambridge University Hospitals NHS Foundation Trust | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 112 | Phase 3 | United Kingdom | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 56 | EUCTR2016-005141-23-EE (EUCTR) | 07/05/2019 | 27/03/2019 | Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) | A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) | Focal segmental glomerulosclerosis (FSGS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Sparsentan Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: SPARSENTAN Trade Name: Irbesartan tablets Product Name: over-encapsulated Irbesartan Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN Trade Name: Irbesartan tablets Product Name: over-encapsulated Irbesartan Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN | Retrophin, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 300 | Phase 3 | United States;Portugal;Hong Kong;Estonia;Taiwan;Spain;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Croatia;Australia;Denmark;Germany;New Zealand;Korea, Republic of;Sweden;Italy | ||
| 57 | EUCTR2018-002476-40-FR (EUCTR) | 07/05/2019 | 14/08/2018 | Personalized Medicine for Membranous Nephropathy PMMN | Personalized Medicine for Membranous Nephropathy PMMN - PMMN | Idiopathic Membranous Nephropathy MedDRA version: 20.0;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857 ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | CHU de Nice | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 64 | Phase 2 | France | |||
| 58 | ChiCTR1900022943 | 2019-05-03 | 2019-05-04 | Population Pharmacokinetic Study for Tacrolimus in Pediatric Patients with Primary Nephrotic Syndrome | Population Pharmacokinetic Study for Tacrolimus in Pediatric Patients with Primary Nephrotic Syndrome | Nephrotic Syndrome | Case Series:Tacrolimus; | Children's Hospital, Zhejiang University School of Medicine | NULL | Recruiting | Both | Case Series:100; | Phase 4 | China | ||
| 59 | EUCTR2018-003437-15-FR (EUCTR) | 03/04/2019 | 27/02/2019 | Rituximab from the FIRst Episode of Idiopathic Nephrotic Syndrome | Rituximab from the FIRst Episode of Idiopathic Nephrotic Syndrome - RIFIREINS | Minimal Change Nephrotic Syndrome (MCNS) MedDRA version: 20.0;Level: LLT;Classification code 10029168;Term: Nephrotic syndrome with lesion of minimal change glomerulonephritis;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 148 | Phase 2 | France | |||
| 60 | ChiCTR1900021757 | 2019-03-01 | 2019-03-08 | A randomized controlled trial for hydroxychloroquine sulfate in the treatment of idiopathic membranous nephropathy | The efficacy and safety of hydroxychloroquine sulfate in idiopathic membranous nephropathy: A randomized, controlled, Single-center clinical trial | Idiopathic Membranous Nephropathy | Group 1:Supportive treatment+Perindopril 8 mg/day;Group 2:Supportive treatment+Perindopril 8 mg/day+hydroxychloroquine sulfate (200mg 2/d);Group 3:Low dose glucocorticoid (0.5mg/kg.d)+cyclosporine A (valley concentration controlled at 50-100ng/ml);Group 4:Low dose glucocorticoid (0.5mg/kg.d)+cyclosporine A (valley concentration controlled at 50-100ng/ml)+hydroxychloroquine sulfate (200mg 2/d); | Nephrology Division, First Hospital Affiliated to Army Medical University | NULL | Recruiting | 18 | 60 | Both | Group 1:55;Group 2:55;Group 3:55;Group 4:55; | Phase 4 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 61 | NCT02683889 (ClinicalTrials.gov) | February 1, 2019 | 5/2/2016 | Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation | The Use of Acthar (ACTH) in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Have Developed Chronic Kidney Disease Stage V (CKD) or End Stage Renal Disease (ESRD) and Are Undergoing a Renal Transplant | FSGS | Drug: Acthar | University of Colorado, Denver | NULL | Recruiting | 18 Years | 80 Years | All | 20 | Phase 3 | United States |
| 62 | EUCTR2017-002674-39-NL (EUCTR) | 30/01/2019 | 18/07/2018 | A treatment study of ACH-0144471 in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | An Open-Label Phase 2 Proof-of-Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471 | biopsy-confirmed C3 Glomerulopathy (C3G) or idiopathic Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) and eGFR >30 mL/min/1.73 m^2 MedDRA version: 20.0;Level: PT;Classification code 10077827;Term: C3 glomerulopathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Danicopan Product Code: ALXN2040 (ACH-0144471) INN or Proposed INN: Not available Other descriptive name: ACH-0144471 Product Name: Danicopan Product Code: ALXN2040 (ACH-0144471) INN or Proposed INN: Not available Other descriptive name: ACH-0144471 | Achillion Pharmaceuticals, a wholly owned subsidiary of Alexion Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 22 | Phase 2 | United States;Belgium;Australia;Netherlands;Italy | ||
| 63 | ChiCTR1800019833 | 2019-01-01 | 2018-12-02 | Dynamic changes of TCM syndrome types of idiopathic membranous nephropathy treated with cyclophosphamide combined with hormone | Dynamic changes of TCM syndrome types of idiopathic membranous nephropathy treated with cyclophosphamide combined with hormone | Idiopathic Membranous Nephropathy | PLA2R???:Cyclophosphamide combined with hormone therapy ;PLA2R positive Group:Cyclophosphamide combined with hormone therapy; | Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical University | NULL | Pending | 18 | 85 | Male | PLA2R???:30;PLA2R positive Group:30; | China | |
| 64 | ChiCTR1800020241 | 2019-01-01 | 2018-12-20 | Investigation for Risk Factors of Membrane Nephropathy in Guangxi and Study for Intervention of Vitamin D | Disease diagnosis and treatment technology and standardized research and development and application demonstration | Idiopathic membranous nephropathy | Vitamin D group:Active Vitamin D 0.5ug/day;Valsartan group:Valsartan capsule 160mg/day;Combined treatment group:Active vitamin D 0.5ug / day + valsartan capsule 160mg / day; | The People's Hospital of Guangxi Zhuang Autonomous Region | NULL | Recruiting | 14 | 100 | Both | Vitamin D group:40;Valsartan group:40;Combined treatment group:40; | China | |
| 65 | NCT03864250 (ClinicalTrials.gov) | November 26, 2018 | 4/3/2019 | Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy | Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy: A Randomized, Open, Controlled, Multicenter Clinical Trial | Tacrolimus;Idiopathic Membranous Nephropathy;Clinical Trial | Drug: Tacrolimus;Drug: Prednisone | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | NULL | Recruiting | 18 Years | 80 Years | All | 124 | N/A | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 66 | EUCTR2016-005141-23-PL (EUCTR) | 20/11/2018 | 25/06/2018 | Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) | A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) | Focal segmental glomerulosclerosis (FSGS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Sparsentan Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: SPARSENTAN Trade Name: Irbesartan tablets Product Name: over-encapsulated Irbesartan Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN Trade Name: Irbesartan tablets Product Name: over-encapsulated Irbesartan Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN | Retrophin, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 300 | Phase 3 | Portugal;United States;Hong Kong;Estonia;Taiwan;Spain;Italy;United Kingdom;France;Hungary;Czech Republic;Canada;Argentina;Poland;Belgium;Brazil;Croatia;Denmark;Australia;Germany;New Zealand;Korea, Republic of;Sweden | ||
| 67 | NCT03649152 (ClinicalTrials.gov) | November 8, 2018 | 7/8/2018 | Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan | A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of Propagermanium in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving Irbesartan | Focal Segmental Glomerulosclerosis | Drug: Propagermanium;Drug: Placebo | Dimerix Bioscience Pty Ltd | Iqvia Pty Ltd | Active, not recruiting | 18 Years | 80 Years | All | 10 | Phase 2 | Australia |
| 68 | EUCTR2016-005141-23-DK (EUCTR) | 05/11/2018 | 02/08/2018 | Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) | A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) | Focal segmental glomerulosclerosis (FSGS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Sparsentan/Over-encapsulated Sparsentan tablets Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: SPARSENTAN Trade Name: Irbesartan tablets Product Name: over-encapsulated Irbesartan Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN Trade Name: Irbesartan tablets Product Name: over-encapsulated Irbesartan Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN Product Name: Sparsentan Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: SPARSENTAN | Travere Therapeutics | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 300 | Phase 3 | United States;Portugal;Czechia;Estonia;Taiwan;Hong Kong;Spain;United Kingdom;Italy;France;Hungary;Czech Republic;Canada;Argentina;Poland;Belgium;Brazil;Croatia;Denmark;Australia;Germany;New Zealand;Sweden;Korea, Republic of | ||
| 69 | EUCTR2017-003021-15-GB (EUCTR) | 23/10/2018 | 14/03/2018 | A study in which the safety and efficacy of CCX140-B is compared with placebo in patients with Focal Segmental Glomerulosclerosis | A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS) | Focal Segmental Glomerulosclerosis (FSGS) MedDRA version: 20.0;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: CCX140-B | ChemoCentryx, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | France;United States;Czech Republic;Canada;Poland;Australia;Germany;New Zealand;Italy;United Kingdom | ||
| 70 | NCT03448692 (ClinicalTrials.gov) | October 15, 2018 | 22/2/2018 | A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS) | A PHASE 2, 12 WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF 06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) | Focal Segmental Glomerulosclerosis (FSGS) | Drug: PF-06730512 | Pfizer | NULL | Recruiting | 18 Years | N/A | All | 44 | Phase 2 | United States;Canada;Japan;Spain |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 71 | NCT03703908 (ClinicalTrials.gov) | October 1, 2018 | 24/7/2018 | A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome | An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome | Focal Segmental Glomerulosclerosis | Drug: CCX140-B | ChemoCentryx | NULL | Recruiting | 18 Years | N/A | All | 13 | Phase 2 | United States |
| 72 | EUCTR2016-005141-23-ES (EUCTR) | 28/09/2018 | 21/06/2018 | Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) | A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) | Focal segmental glomerulosclerosis (FSGS) MedDRA version: 20.0;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Sparsentan Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: SPARSENTAN Trade Name: Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03 Product Name: over-encapsulated 75 mg Irbesartan Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN | Retrophin, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 300 | Phase 3 | United States;Taiwan;Spain;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Denmark;South Africa;Germany;Korea, Republic of | ||
| 73 | EUCTR2016-005141-23-GB (EUCTR) | 18/09/2018 | 02/05/2018 | Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) | A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) - DUPLEX (021FSGS16010) Sparsentan in FSGS | Focal segmental glomerulosclerosis (FSGS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Sparsentan/Over-encapsulated Sparsentan tablets Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: SPARSENTAN Trade Name: Irbesartan tablets Product Name: Irbesartan tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN Trade Name: Irbesartan tablets Product Name: Irbesartan tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN Product Name: Sparsentan Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: SPARSENTAN | Retrophin, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 300 | Phase 3 | United States;Portugal;Taiwan;Estonia;Hong Kong;Spain;Italy;United Kingdom;France;Hungary;Czech Republic;Canada;Argentina;Poland;Belgium;Brazil;Croatia;Australia;Denmark;Germany;New Zealand;Sweden;Korea, Republic of | ||
| 74 | EUCTR2016-005141-23-CZ (EUCTR) | 05/09/2018 | 13/06/2018 | Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) | A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) | Focal segmental glomerulosclerosis (FSGS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Sparsentan/Over-encapsulated Sparsentan tablets Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: SPARSENTAN Trade Name: Irbesartan tablets Product Name: over-encapsulated Irbesartan Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN Trade Name: Irbesartan tablets Product Name: over-encapsulated Irbesartan Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN Product Name: Sparsentan Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: SPARSENTAN | Retrophin, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 300 | Phase 3 | Portugal;United States;Hong Kong;Estonia;Taiwan;Spain;Italy;United Kingdom;France;Hungary;Czech Republic;Canada;Argentina;Poland;Belgium;Brazil;Croatia;Australia;Denmark;Germany;New Zealand;Korea, Republic of;Sweden | ||
| 75 | EUCTR2016-005141-23-HU (EUCTR) | 29/08/2018 | 26/06/2018 | Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) | A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) | Focal segmental glomerulosclerosis (FSGS) MedDRA version: 20.0;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Retrophin, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 3 | Portugal;United States;Estonia;Taiwan;Spain;United Kingdom;Italy;France;Hungary;Czech Republic;Canada;Belgium;Poland;Australia;Denmark;South Africa;Germany;Sweden;Korea, Republic of | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 76 | NCT03298698 (ClinicalTrials.gov) | August 22, 2018 | 24/8/2017 | Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome | Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Unresponsive to 8 Weeks of High Dose Prednisone | Idiopathic Nephrotic Syndrome;Minimal Change Disease;Focal Segmental Glomerulosclerosis | Drug: Rituximab;Drug: Prednisone | Radboud University | NULL | Recruiting | 18 Years | N/A | All | 40 | Phase 3 | Netherlands |
| 77 | EUCTR2017-001821-42-GB (EUCTR) | 02/08/2018 | 12/09/2017 | A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of a group of related conditions that cause the kidneys to malfunction, called C3 Glomerulopathy. | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy | C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD, formerly called membranoproliferative glomerulonephritis [MPGN] Type II) and C3 glomerulonephritis (C3GN, formerly called idiopathic MPGN). MedDRA version: 20.0;Level: PT;Classification code 10077827;Term: C3 glomerulopathy;System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | ChemoCentryx, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 88 | Phase 2 | France;United States;Canada;Belgium;Spain;Ireland;Denmark;Netherlands;Germany;Italy;United Kingdom | |||
| 78 | EUCTR2017-002674-39-BE (EUCTR) | 31/07/2018 | 16/05/2018 | A treatment study of ACH-0144471 in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | An Open-Label Phase 2 Proof-of-Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471 | biopsy-confirmed C3 Glomerulopathy (C3G) or idiopathic Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) and eGFR >30 mL/min/1.73 m^2 MedDRA version: 20.0;Level: PT;Classification code 10077827;Term: C3 glomerulopathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: ACH-0144471 INN or Proposed INN: Not available Other descriptive name: ACH-0144471 Product Code: ACH-0144471 INN or Proposed INN: Not available Other descriptive name: ACH-0144471 | Achillion Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 20 | Phase 2 | United States;Belgium;Australia;Netherlands;Italy | ||
| 79 | NCT03549663 (ClinicalTrials.gov) | July 4, 2018 | 10/5/2018 | Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN) | Random, Open, Control and Monocentric Clinical Research on Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN) | Idiopathic Membranous Nephropathy | Drug: Tacrolimus;Drug: Prednisone | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | NULL | Recruiting | 18 Years | 80 Years | All | 108 | N/A | China |
| 80 | EUCTR2017-003021-15-IT (EUCTR) | 04/07/2018 | 10/11/2020 | A study to evaluate the efficacy og CCX140-B in patients with FSGS | A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS) - NA | Focal Segmental Glomerulosclerosis (FSGS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: - Product Code: [CCX140-B] | CHEMOCENTRYX, INC. | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | United States;France;Czechia;Canada;Poland;Australia;Germany;United Kingdom;New Zealand;Italy | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 81 | ChiCTR1800016140 | 2018-07-01 | 2018-05-14 | Comparison of the efficacy and safety of tacrolimus and glucocorticoid combined with cyclophosphamide in the treatment of adult primary membranous nephropathy: a multicenter, controlled, open study | A randomized controlled trial for the treatment of primary membranous nephropathy | primary membranous nephropathy | Tacrolimus group:Tacrolimus 0.05-0.1mg/kg/d;Cyclophosphamide group:CTX 750mg/m2 ivgtt q2w for 8 weeks, then q4w for 4 weeks; | Sichuan Provincial People's Hospital | NULL | Pending | 18 | 65 | Both | Tacrolimus group:45;Cyclophosphamide group:45; | China | |
| 82 | NCT03170323 (ClinicalTrials.gov) | July 1, 2018 | 26/5/2017 | Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy | A Prospective Randomized, Controlled Trial of Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy | Idiopathic Membranous Nephropathy | Drug: Mycophenolate Mofetil;Drug: Cyclosporins | Guangdong Provincial People's Hospital | NULL | Recruiting | 18 Years | N/A | All | 128 | Phase 4 | China |
| 83 | EUCTR2016-003525-42-NL (EUCTR) | 26/06/2018 | 09/01/2018 | A treatment study of ACH-0144471 in Patients with Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients with Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | biopsy-confirmed C3 Glomerulopathy (C3G) or idiopathic Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) and a low serum C3 level MedDRA version: 20.0;Level: PT;Classification code 10077827;Term: C3 glomerulopathy;System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Achillion Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 10 | Phase 2 | Belgium;Australia;Netherlands | |||
| 84 | NCT03598036 (ClinicalTrials.gov) | June 21, 2018 | 14/6/2018 | Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis | An Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects With Focal Segmental Glomerulosclerosis | Focal Segmental Glomerulosclerosis | Drug: Voclosporin | Aurinia Pharmaceuticals Inc. | NULL | Terminated | 18 Years | 75 Years | All | 5 | Phase 2 | United States;Dominican Republic |
| 85 | NCT03459443 (ClinicalTrials.gov) | June 20, 2018 | 26/2/2018 | A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471 | C3 Glomerulonephritis;C3 Glomerulopathy;Immune Complex Membranoproliferative Glomerulonephritis;IC-MPGN;Dense Deposit Disease | Drug: ACH-0144471 | Alexion Pharmaceuticals | NULL | Active, not recruiting | 17 Years | 65 Years | All | 22 | Phase 2 | United States;Australia;Belgium;Italy;Netherlands |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 86 | EUCTR2017-003021-15-PL (EUCTR) | 19/06/2018 | 18/05/2018 | A controlled study to evaluate the safety and efficacy of the study drug, CCX140-B, in subjects with Focal Segmental Glomerulosclerosis (a type of glomerular disease) | A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS) | Focal Segmental Glomerulosclerosis (FSGS) MedDRA version: 20.0;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: CCX140-B INN or Proposed INN: INN not available yet | ChemoCentryx, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | France;United States;Czech Republic;Canada;Poland;Australia;Germany;New Zealand;Italy;United Kingdom | ||
| 87 | EUCTR2017-003021-15-FR (EUCTR) | 18/05/2018 | 13/03/2018 | Study to determine the dose CCX140-B and to evaluate the its safety and efficacy of in Subjects with Focal Segmental Glomerulosclerosis (FSGS) | A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS) | Focal Segmental Glomerulosclerosis (FSGS) MedDRA version: 20.0;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: CCX140-B | ChemoCentryx, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | United States;France;Czech Republic;Canada;Poland;Australia;Germany;New Zealand;Italy;United Kingdom | ||
| 88 | NCT03536754 (ClinicalTrials.gov) | May 1, 2018 | 28/3/2018 | A Study of CCX140-B in Subjects With FSGS | A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis (FSGS) | FSGS;Focal Segmental Glomerulosclerosis;Glomerulosclerosis | Other: Placebo;Drug: CCX140-B | ChemoCentryx | Medpace, Inc. | Active, not recruiting | 18 Years | 75 Years | All | 46 | Phase 2 | United States;Australia;Canada;France;Italy;New Zealand;Poland;United Kingdom |
| 89 | NCT03422510 (ClinicalTrials.gov) | April 15, 2018 | 30/1/2018 | FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS) | A Phase 2 Multicenter, Open Label, Randomized Study of Two Titration Regimens of Oral CXA-10 in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS) | Primary Focal Segmental Glomerulosclerosis | Drug: CXA-10 | Complexa, Inc. | Kidney Research Network, formerly NephCure Accelerating Cures Institute;Medpace, Inc.;MicroConstants;Arkana Labs;NephCure Kidney International | Completed | 13 Years | N/A | All | 33 | Phase 2 | United States |
| 90 | NCT03493685 (ClinicalTrials.gov) | March 29, 2018 | 3/4/2018 | Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) | A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS | Focal Segmental Glomerulosclerosis | Drug: sparsentan;Drug: Irbesartan | Travere Therapeutics, Inc. | NULL | Active, not recruiting | 8 Years | 75 Years | All | 300 | Phase 3 | United States;Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;Hungary |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 91 | NCT03466801 (ClinicalTrials.gov) | March 20, 2018 | 13/1/2018 | The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I. | The Efficacy of Prednisone Alone and Combination Therapy With Methylprednisolone and Cyclophosphamide in the Treatment of Membranous Nephropathy in Stage I. | Idiopathic Membranous Nephropathy | Drug: Prednisone;Drug: MP and CTX | Wenhu Liu | NULL | Unknown status | 18 Years | 80 Years | All | 166 | N/A | NULL |
| 92 | NCT03025828 (ClinicalTrials.gov) | March 19, 2018 | 17/1/2017 | Adrenocorticotropic Hormone in Membranous Nephropathy | Changes in Autoreactive Memory B Cells as Biomarker of Response to Adrenocorticotropic Hormone in Patients With Membranous Nephropathy | Membranous Nephropathy | Drug: ACTHar | Icahn School of Medicine at Mount Sinai | NULL | Recruiting | 18 Years | 70 Years | All | 25 | Phase 4 | United States |
| 93 | EUCTR2017-001821-42-IT (EUCTR) | 07/03/2018 | 14/11/2017 | A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of a group of related conditions that cause the kidneys to malfunction, called C3 Glomerulopathy. | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy | C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD, formerly called membranoproliferative glomerulonephritis [MPGN] Type II) and C3 glomerulonephritis (C3GN, formerly called idiopathic MPGN). MedDRA version: 20.0;Level: PT;Classification code 10077827;Term: C3 glomerulopathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Avacopan Product Code: CCX168 INN or Proposed INN: AVACOPAN | ChemoCentryx, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 44 | Phase 2 | France;United States;Canada;Belgium;Spain;Ireland;Denmark;Netherlands;Germany;United Kingdom;Italy | ||
| 94 | EUCTR2017-001821-42-NL (EUCTR) | 13/02/2018 | 16/10/2017 | A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of a group of related conditions that cause the kidneys to malfunction, called C3 Glomerulopathy. | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy | C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD, formerly called membranoproliferative glomerulonephritis [MPGN] Type II) and C3 glomerulonephritis (C3GN, formerly called idiopathic MPGN). MedDRA version: 20.0;Level: PT;Classification code 10077827;Term: C3 glomerulopathy;System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | ChemoCentryx, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 88 | Phase 2 | France;United States;Canada;Belgium;Spain;Ireland;Denmark;Germany;Netherlands;Italy;United Kingdom | |||
| 95 | ChiCTR1800014719 | 2018-02-01 | 2018-01-31 | A retrospective control study of low concentration of tacrolimus combined with prednisone in the treatment of idiopathic focal segmental glomerulosclerosis | A retrospective control study of low concentration of tacrolimus combined with prednisone in the treatment of idiopathic focal segmental glomerulosclerosis | idiopathic focal segmental glomerulosclerosis | tacrolimus group:nothing;prednisone group:nothing; | the First Affiliated Hospital of Third Military Medical University | NULL | Recruiting | Both | tacrolimus group:24;prednisone group:17; | China | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 96 | NCT03453619 (ClinicalTrials.gov) | January 22, 2018 | 27/2/2018 | Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies | A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease) | IgA Nephropathy;Lupus Nephritis;Membranous Nephropathy;C3 Glomerulonephritis;Dense Deposit Disease | Drug: APL-2 | Apellis Pharmaceuticals, Inc. | NULL | Active, not recruiting | 18 Years | N/A | All | 21 | Phase 2 | United States |
| 97 | EUCTR2017-001821-42-BE (EUCTR) | 15/01/2018 | 06/10/2017 | A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of a group of related conditions that cause the kidneys to malfunction, called C3 Glomerulopathy. | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy | C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD, formerly called membranoproliferative glomerulonephritis [MPGN] Type II) and C3 glomerulonephritis (C3GN, formerly called idiopathic MPGN). MedDRA version: 20.0;Level: PT;Classification code 10077827;Term: C3 glomerulopathy;System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | ChemoCentryx, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 88 | Phase 2 | France;United States;Canada;Spain;Belgium;Ireland;Denmark;Netherlands;Germany;Italy;United Kingdom | |||
| 98 | NCT03366337 (ClinicalTrials.gov) | December 26, 2017 | 4/12/2017 | A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX | A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases | IgA Nephropathy;CKD Associated With Type 1 Diabetes;Focal Segmental Glomerulosclerosis;Autosomal Dominant Polycystic Kidney | Drug: Bardoxolone methyl capsules | Reata Pharmaceuticals, Inc. | NULL | Completed | 18 Years | 65 Years | All | 103 | Phase 2 | United States |
| 99 | EUCTR2017-001821-42-DK (EUCTR) | 19/12/2017 | 25/10/2017 | A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of a group of related conditions that cause the kidneys to malfunction, called C3 Glomerulopathy. | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy | C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD, formerly called membranoproliferative glomerulonephritis [MPGN] Type II) and C3 glomerulonephritis (C3GN, formerly called idiopathic MPGN). MedDRA version: 20.0;Level: PT;Classification code 10077827;Term: C3 glomerulopathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Avacopan Product Code: CCX168 INN or Proposed INN: AVACOPAN | ChemoCentryx, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 88 | Phase 2 | United States;France;Canada;Spain;Belgium;Ireland;Denmark;Netherlands;Germany;United Kingdom;Italy | ||
| 100 | EUCTR2017-001821-42-ES (EUCTR) | 04/12/2017 | 24/10/2017 | A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of a group of related conditions that cause the kidneys to malfunction, called C3 Glomerulopathy. | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy | C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD, formerly called membranoproliferative glomerulonephritis [MPGN] Type II) and C3 glomerulonephritis (C3GN, formerly called idiopathic MPGN). MedDRA version: 20.0;Level: PT;Classification code 10077827;Term: C3 glomerulopathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Avacopan Product Code: CCX168 INN or Proposed INN: AVACOPAN | ChemoCentryx, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 44 | Phase 2 | France;United States;Canada;Belgium;Spain;Ireland;Denmark;Netherlands;Germany;Italy;United Kingdom | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 101 | EUCTR2017-001821-42-IE (EUCTR) | 01/12/2017 | 09/01/2018 | A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of a group of related conditions that cause the kidneys to malfunction, called C3 Glomerulopathy. | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy | C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD, formerly called membranoproliferative glomerulonephritis [MPGN] Type II) and C3 glomerulonephritis (C3GN, formerly called idiopathic MPGN). MedDRA version: 20.0;Level: PT;Classification code 10077827;Term: C3 glomerulopathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Avacopan Product Code: CCX168 INN or Proposed INN: AVACOPAN | ChemoCentryx, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 88 | Phase 2 | United States;France;Canada;Spain;Belgium;Ireland;Denmark;Netherlands;Germany;United Kingdom;Italy | ||
| 102 | ChiCTR1900027627 | 2017-12-01 | 2019-11-22 | Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy | Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy | f PLA2R-associated primary membranous nephropathy | experimental group:LEF combined with prednisone;control group:yclophosphamide (CTX) combined with prednisone; | Department of Nephrology, The First Affiliated Hospital of Bengbu Medical College | NULL | Completed | Both | experimental group:30;control group:30; | Phase 4 | China | ||
| 103 | EUCTR2017-001821-42-DE (EUCTR) | 22/11/2017 | 09/10/2017 | A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of a group of related conditions that cause the kidneys to malfunction, called C3 Glomerulopathy. | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy | C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD, formerly called membranoproliferative glomerulonephritis [MPGN] Type II) and C3 glomerulonephritis (C3GN, formerly called idiopathic MPGN). MedDRA version: 20.0;Level: PT;Classification code 10077827;Term: C3 glomerulopathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Avacopan Product Code: CCX168 INN or Proposed INN: AVACOPAN | ChemoCentryx, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 88 | Phase 2 | United States;France;Canada;Spain;Belgium;Ireland;Denmark;Netherlands;Germany;United Kingdom;Italy | ||
| 104 | NCT03285711 (ClinicalTrials.gov) | October 6, 2017 | 14/9/2017 | Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN) | A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN) | Lupus Membranous Nephropathy | Drug: Filgotinib;Drug: Lanraplenib;Drug: Filgotinib placebo;Drug: Lanraplenib placebo | Gilead Sciences | NULL | Completed | 18 Years | 75 Years | All | 9 | Phase 2 | United States |
| 105 | ChiCTR-INR-17012070 | 2017-09-19 | 2017-07-20 | Yongquan acupoint Shenque moxibustion curative effect of traditional Chinese medicine in the treatment of membranous nephropathy | Yongquan acupoint Shenque moxibustion curative effect of traditional Chinese medicine in the treatment of membranous nephropathy | Membranous nephropathy | Test group :Yongquan Shenque paste of Chinese medicine with mild moxibustion;control group:Valsartan Tablets; | Shijiazhuang Nephropathy Hospital | NULL | Pending | 18 | 75 | Both | Test group :75;control group:75; | China | |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 106 | NCT03095118 (ClinicalTrials.gov) | September 7, 2017 | 20/3/2017 | Daratumumab in Treatment of PGNMID and C3 GN | Single-center Phase 2 Open-label Trial Evaluating Efficacy and Safety of Daratumumab in Treatment of Patients With Proliferative Glomerulonephritis With Monoclonal Immune Deposits and C3 Glomerulopathy Associated With Monoclonal Gammopathy | Membranoproliferative Glomerulonephritis | Drug: Daratumumab | Fernando Fervenza | NULL | Active, not recruiting | 18 Years | N/A | All | 10 | Phase 2 | United States |
| 107 | NCT03124368 (ClinicalTrials.gov) | August 9, 2017 | 12/4/2017 | A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN | A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | C3 Glomerulonephritis;Dense Deposit Disease;Membranoproliferative Glomerulonephritis, Type II;C3 Glomerulopathy;Immune Complex Mediated Membranoproliferative Glomerulonephritis | Drug: ACH-0144471 | Alexion Pharmaceuticals | NULL | Completed | 16 Years | 65 Years | All | 6 | Phase 2 | Australia;Belgium;Netherlands |
| 108 | ChiCTR-INR-17012212 | 2017-07-28 | 2017-08-01 | Use of sirolimus in patients with primary idiopathic membranous nephropathy: a prospective randomized control trial | Use of sirolimus in patients with primary idiopathic membranous nephropathy: a prospective randomized control trial | idiopathic membranous nephropathy | 1:Cyclosporine;2:cyclosporine combined with sirolimus; | Renal Division, Peking University First Hospital | NULL | Recruiting | 18 | 70 | Both | 1:35;2:35; | China | |
| 109 | ChiCTR-IPR-17011702 | 2017-07-01 | 2017-06-19 | Compare of the treatment of membranous nephropathy with mizoribine and steroid or cyclophosphamide and steroid | Compare of the treatment of membranous nephropathy with mizoribine and steroid or cyclophosphamide and steroid | membranous nephropathy | mizoribine group:treated with mizoribine and steroid;cyclophosphamide group:treated with cyclophosphamide and steroid; | Tianjin First Central Hospital | NULL | Pending | 18 | 65 | Both | mizoribine group:50;cyclophosphamide group:50; | China | |
| 110 | NCT03180723 (ClinicalTrials.gov) | July 1, 2017 | 3/6/2017 | Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis | Effect of Rituximab in Treatment of Primary Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis | Drug: Rituximab;Drug: Cyclosporin | Assiut University | NULL | Not yet recruiting | 18 Years | N/A | All | 30 | Phase 3 | NULL |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 111 | ChiCTR-IPR-17011386 | 2017-06-01 | 2017-05-12 | Study on the Effect and Mechanism of Interleukin - 2 in the Treatment of Idiopathic Membranous Nephropathy | Study on the Effect and Mechanism of Interleukin - 2 in the Treatment of Idiopathic Membranous Nephropathy | Membranous Nephropathy | treatment group:oral CsA, glucosteroid aInterleukin 2nd;Control group:oral CsA and glucosteroid; | Shijiazhuang kidney disease hospital Limited company | NULL | Recruiting | 18 | 60 | Both | treatment group:50;Control group:50; | China | |
| 112 | NCT02921789 (ClinicalTrials.gov) | May 22, 2017 | 30/9/2016 | Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients | A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients | Kidney Transplantation;Focal Segmental Glomerulosclerosis (FSGS) | Drug: Bleselumab;Drug: Basiliximab;Drug: Mycophenolate Mofetil (MMF);Drug: Tacrolimus Capsules;Drug: Methylprednisone;Drug: Prednisone | Astellas Pharma Global Development, Inc. | Kyowa Kirin Co., Ltd. | Recruiting | 18 Years | N/A | All | 60 | Phase 2 | United States;Canada |
| 113 | NCT02896270 (ClinicalTrials.gov) | October 2016 | 6/9/2016 | Valproic Acid for Idiopathic Nephrotic Syndrome | A Prospective Interventional Pilot Study on the Use of Valproic Acid for Treatment of Idiopathic Nephrotic Syndrome | Idiopathic Nephrotic Syndrome;Focal Segmental Glomerulosclerosis;Minimal Change Disease | Drug: Valproic Acid | Universitair Ziekenhuis Brussel | NULL | Recruiting | 18 Years | N/A | All | 15 | Phase 2;Phase 3 | Belgium |
| 114 | NCT02966717 (ClinicalTrials.gov) | August 2016 | 30/10/2016 | Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD) | The Clinical Study of Rituximab Combined With Mesenchymal Stem Cells in the Treatment of Primary Nephrotic Syndrome (3-4 Stage of Chronic Kidney Disease) | Renal Insufficiency, Chronic;Nephrotic Syndrome | Drug: Rituximab;Drug: conventional therapy;Drug: Mesenchymal stem cells | Zhujiang Hospital | NULL | Active, not recruiting | 18 Years | 65 Years | Both | 116 | Phase 2 | China |
| 115 | ChiCTR-IPR-16008527 | 2016-06-01 | 2016-05-24 | Rituximab in the treatment of refractory membranous nephropathy: a multicenter, randomized, controlled clinical study | Rituximab in the treatment of resistant membranous nephropathy: a multicenter, randomized, controlled clinical study | Membranous nephropathy | CsA group:oral CsA and glucosteroid;RTX group:intravenous RTX; | Ruijin Hospital, affiliated to Shanghai Jiaotong University, School of medicine | NULL | Recruiting | 18 | 70 | Both | CsA group:60;RTX group:60; | China | |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 116 | NCT02633046 (ClinicalTrials.gov) | May 16, 2016 | 15/12/2015 | Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria | Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segmental Glomerulosclerosis: A Prospective Study of Acthar (PODOCYTE) | Idiopathic Focal Segmental Glomerulosclerosis | Drug: Acthar Gel | Mallinckrodt ARD LLC | NULL | Completed | 18 Years | N/A | All | 64 | Phase 4 | United States;Argentina;Australia;Chile;Mexico;Peru;Turkey;Canada;Hong Kong;New Zealand;Puerto Rico |
| 117 | JPRN-UMIN000022150 | 2016/04/30 | 01/05/2016 | The prospective single-center study on the efficacy and safety of rituximab for the treatment of adult and geriatric patients with primary nephrotic syndrome. | The prospective single-center study on the efficacy and safety of rituximab for the treatment of adult and geriatric patients with primary nephrotic syndrome. - The study on efficacy and safety of rituximab for adult and geriatric patients with nephrotic syndrome. | primary nephrotic syndrome | rituximab | Tokyo Metropolitan Geriatric Hospital | NULL | Complete: follow-up complete | 18years-old | Not applicable | Male and Female | 50 | Not applicable | Japan |
| 118 | ChiCTR-IPR-16008344 | 2016-04-19 | 2016-04-22 | A study for comparing alternating glucocorticoid and cyclophosphamide versus glucocorticoid plus tacrolimus in idiopathic membranous nephropathy | A study for comparing alternating glucocorticoid and cyclophosphamide versus glucocorticoid Plus tacrolimus in idiopathic membranous nephropathy | idiopathic membranous nephropathy | A:cyclophosphamide ;B:tacrolimus; | Baoji Central Hospital | NULL | Recruiting | Both | A:30;B:30; | China | |||
| 119 | NCT02592798 (ClinicalTrials.gov) | March 1, 2016 | 29/10/2015 | Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) | A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome (Focal Segmental Glomerulosclerosis/ Minimal Change Disease) | Nephrotic Syndrome;Focal Segmental Glomerulosclerosis;Minimal Change Disease | Drug: Abatacept;Other: Normal Saline;Other: D5W | Bristol-Myers Squibb | NULL | Completed | 6 Years | N/A | All | 36 | Phase 2 | United States |
| 120 | NCT02682407 (ClinicalTrials.gov) | February 2016 | 10/2/2016 | Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 | A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease | IgAN;Lupus Nephritis;MN;C3 Glomerulopathy | Biological: OMS721 (narsoplimab) | Omeros Corporation | NULL | Recruiting | 18 Years | N/A | All | 54 | Phase 2 | United States;Hong Kong |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 121 | NCT02610595 (ClinicalTrials.gov) | December 2015 | 18/11/2015 | Study on the Therapeutic Effect of TCM Treatment for MDR MN | A Prospective, Multi-center Study of the Chinese Medicine for the Treatment of MDR Membranous Nephropathy in the Traditional Chinese Medicine (a Herbal Formula for Invigorating Spleen and Benefiting qi and Promoting Blood Circulation) | Idiopathic Membranous Nephropathy | Drug: Jianpixiaozhong particles and Wuse Dietotherapy | Shanghai University of Traditional Chinese Medicine | Fudan University;Ruijin Hospital;Shanghai 6th People's Hospital;Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;Changhai Hospital;Shanghai Putuo District Center Hospital;ShuGuang Hospital;Shanghai Yueyang Integrated Medicine Hospital;Shanghai Changzheng Hospital;Shanghai Minhang Central Hospital;Zhujiang Hospital;Guangxi Traditional Chinese Medical University;Huashan Hospital;The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine;Xinqiao Hospital of Chongqing;Guang'anmen Hospital of China Academy of Chinese Medical Sciences;Nanjing University of Traditional Chinese Medicine;Tongji Hospital;Chinese Academy of Sciences;RenJi Hospital | Not yet recruiting | 18 Years | 75 Years | Both | 220 | N/A | China |
| 122 | NCT02585804 (ClinicalTrials.gov) | September 2015 | 22/10/2015 | Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects | Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: The TRANSLATE Study | Focal Segmental Glomerulosclerosis | Drug: Dapagliflozin | University Health Network, Toronto | AstraZeneca;University of Toronto;Toronto General Hospital | Completed | 18 Years | N/A | All | 10 | Phase 4 | Canada |
| 123 | NCT02382874 (ClinicalTrials.gov) | May 2015 | 3/3/2015 | Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis) | Allogenic Adipose Derived Mesenchymal Stromal Cells Transplantation to Improve Kidney Function in Refractory Primary Nephrotic Syndrome (Focal Segmental Glomerulosclerosis,FSGS) ,a Phase I Clinical Trial | Focal Segmental Glomerulosclerosis | Biological: Intravenous injection | Royan Institute | NULL | Recruiting | 2 Years | 14 Years | Both | 5 | Phase 1 | Iran, Islamic Republic of |
| 124 | EUCTR2014-002358-38-CZ (EUCTR) | 28/04/2015 | 14/10/2014 | PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN (RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL, DOSE-ESCALATION STUDY | PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN (RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL, DOSE-ESCALATION STUDY | FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Sparsentan Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: SPARSENTAN Trade Name: Aprovel (150 mg) Product Name: Aprovel 150 mg Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN Product Name: Sparsentan Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: SPARSENTAN | Retrophin, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 2 | Czech Republic;Belgium;Italy | ||
| 125 | EUCTR2013-000226-55-NL (EUCTR) | 04/03/2015 | 24/06/2014 | SEQUENTIAL THERAPY WITH TACROLIMUS AND RITUXIMAB IN PRIMARY MEMBRANOUS NEPHROPATHY | European Multicenter and Open-Label Controlled Randomized Trial to evaluate the Efficacy of Sequential Treatment with Tacrolimus-Rituximab versus Steroids plus Cyclophosphamide in patientes with Primary Membranous Nephropathy - STARMEN | Primary membranous nephropathy MedDRA version: 17.0;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Trade Name: Tacrolimus Product Name: TACROLIMUS INN or Proposed INN: TACROLIMUS Other descriptive name: TACROLIMUS Trade Name: MabThera Product Name: Rituximab INN or Proposed INN: RITUXIMAB Trade Name: Methylprednisolone Product Name: Methylprednisolone INN or Proposed INN: methylprednisolone Other descriptive name: METHYLPREDNISOLONE Trade Name: Prednisolone Product Name: Prednisolone INN or Proposed INN: prednisolone Other descriptive name: PREDNISOLONE ACETATE Trade Name: cyclophosphamide Product Name: cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE | Fundacion Renal Iñigo Alvarez Toledo | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 175 | Spain;Netherlands | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 126 | NCT02235857 (ClinicalTrials.gov) | March 2015 | 6/9/2014 | Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children | Treatment of Drug-resistant Pediatric Primary Focal Segmental Glomerulosclerosis Using the Liposorber® LA-15 System | Focal Segmental Glomerulosclerosis | Device: LIPOSORBER® LA-15 System | Kaneka Pharma America LLC | NULL | Recruiting | N/A | 21 Years | All | 35 | N/A | United States |
| 127 | EUCTR2014-002358-38-BE (EUCTR) | 05/02/2015 | 25/11/2014 | PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN (RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL, DOSE-ESCALATION STUDY | PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN (RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL, DOSE-ESCALATION STUDY | FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) MedDRA version: 17.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Sparsentan Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: SPARSENTAN Trade Name: Aprovel (150 mg) Product Name: Aprovel 150 mg Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN | Retrophin, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Czech Republic;Belgium;Italy | |||
| 128 | EUCTR2014-002358-38-IT (EUCTR) | 15/12/2014 | 19/11/2014 | PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN (RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL, DOSE-ESCALATION STUDY | PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN (RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL, DOSE-ESCALATION STUDY | FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) MedDRA version: 17.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Sparsentan Product Code: RE-021 Trade Name: Aprovel (150 mg) Product Name: Aprovel 150 mg Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN | Retrophin, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Czech Republic;Belgium;Italy | |||
| 129 | ChiCTR-IPR-14005366 | 2014-09-01 | 2014-01-10 | A prospective study of safety and efficacy in atypical membranous nephropathy by low-dose hormone combined immunosuppressive therapy | A prospective study of safety and efficacy in atypical membranous nephropathy by low-dose hormone combined immunosuppressive therapy | Atypical membranous nephropathy | Low-dose hormone plus cyclophosphamide (CTX) grou:hormone, cyclophosphamide, three months;hormone+CsA:hormone+CsA, three months; | Department of Nephrology, China-Japan Friendship Hospital | NULL | Recruiting | 18 | 70 | Both | Low-dose hormone plus cyclophosphamide (CTX) grou:20;hormone+CsA:20; | NULL | |
| 130 | ChiCTR-TRC-14005064 | 2014-09-01 | 2014-08-06 | A prospective study on the safety and efficacy of treatment with Qiluxiaobai formula for CKD 2-3 stage | Investigation on the Mechanisms Of Invigorating Spleen Dissipating Dampness Principle On The Treatment Of Podocyte Injury In Focal Segmental Glomerulosclerosis | chronic kidney disease | 1:basic treatment and losartan K 50mg qd;2:basic treatment and QLXB formula 200ml qd ; | Shanghai University of T.C.M | NULL | Recruiting | 18 | 60 | Both | 1:50;2:50; | China | |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 131 | NCT02000440 (ClinicalTrials.gov) | July 1, 2014 | 27/11/2013 | A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS) | Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS) | Glomerulosclerosis, Focal Segmental | Drug: Losmapimod | GlaxoSmithKline | NULL | Completed | 18 Years | 70 Years | All | 17 | Phase 2 | United States;Canada |
| 132 | NCT02173106 (ClinicalTrials.gov) | June 2014 | 23/6/2014 | A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy | Opportunity, Validity and Security of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial | Idiopathic Membranous Nephropathy;Proteinuria;Spontaneous Remission;Steroid Nephropathy;Cyclosporin Overdose | Drug: steroid & Cyclosporin | Sun Yat-sen University | NULL | Recruiting | 14 Years | 75 Years | Both | 180 | Phase 2 | China |
| 133 | NCT02093533 (ClinicalTrials.gov) | March 2014 | 17/3/2014 | Eculizumab in Primary MPGN | EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA | Membranoproliferative Glomerulonephritis | Drug: Eculizumab | Mario Negri Institute for Pharmacological Research | Alexion Pharma Italy s.r.l. | Completed | N/A | 75 Years | All | 10 | Phase 2 | Italy |
| 134 | EUCTR2013-003826-10-IT (EUCTR) | 24/01/2014 | 28/10/2013 | ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS | EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA - Eculizumab in primary MPGN | Membranoproliferative glomerulonephritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | IRCCS- Mario Negri Institute | NULL | Not Recruiting | Female: yes Male: yes | 10 | Phase 2 | Italy | |||
| 135 | NCT01955187 (ClinicalTrials.gov) | January 2014 | 19/9/2013 | Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy | European Multicenter and Open-Label Controlled Randomized Trial to Evaluate the Efficacy of Sequential Treatment With Tacrolimus-Rituximab Versus Steroids Plus Cyclophosphamide in Patients With Primary Membranous Nephropathy (The STARMEN Study) | MEMBRANOUS NEPHROPATHY | Drug: TACROLIMUS;Drug: RITUXIMAB;Drug: METHYLPREDNISOLONE;Drug: CYCLOPHOSPHAMIDE | Hospital Universitario 12 de Octubre | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz;Hospital Universitario Fundación Alcorcón;Fundación para la Investigación Biomédica Hospital Universitario 12 de Octubre;Biobanco REDinREN;ERA-EDTA;REDinREN;Sociedad Española de Nefrología;Fundación de Investigación Biomédica - Hospital Universitario de La Princesa;University Hospital, Aachen | Completed | 18 Years | N/A | All | 86 | Phase 3 | Spain |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 136 | NCT01613118 (ClinicalTrials.gov) | December 2013 | 4/6/2012 | Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis | Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study | Focal Segmental Glomerulosclerosis | Drug: RE-021 (Sparsentan);Drug: Irbesartan | Travere Therapeutics, Inc. | NULL | Active, not recruiting | 8 Years | 75 Years | All | 100 | Phase 2 | United States;Belgium;Czechia;Italy;Czech Republic |
| 137 | NCT01573533 (ClinicalTrials.gov) | October 2013 | 5/4/2012 | A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS | A Pilot Study to Assess the Efficacy of Rituximab Therapy in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS): Integrating an Assessment of the Relevance of suPAR and Activation of Podocyte ß3 Integrin | Primary Focal Segmental Glomerulosclerosis | Biological: Rituximab | Mayo Clinic | University Health Network, Toronto;National Institutes of Health (NIH);Genentech, Inc.;Rush University Medical Center;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | 6 Years | 80 Years | All | 9 | Phase 2 | United States;Canada |
| 138 | EUCTR2012-002365-35-DE (EUCTR) | 15/07/2013 | 11/03/2013 | A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) | A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis | Focal segmental glomerulosclerosis MedDRA version: 14.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Not possible to specify | Product Name: Fresolimumab Product Code: GC1008 INN or Proposed INN: Fresolimumab Other descriptive name: GZ402669 | Genzyme Corporation | NULL | Not Recruiting | Female: yes Male: yes | 125 | Phase 2 | France;United States;Brazil;Spain;Germany;Italy | ||
| 139 | NCT01622738 (ClinicalTrials.gov) | July 2013 | 13/6/2012 | A Study of RE-021 in Patients With Focal Segmental Glomerulosclerosis | A Study of RE-021 in Patients With Focal Segmental Glomerulosclerosis | Primary Focal Segmental Glomerulosclerosis | Drug: RE-021 | Retrophin, Inc. | NULL | Withdrawn | N/A | 50 Years | Both | 0 | N/A | United States |
| 140 | EUCTR2012-002365-35-IT (EUCTR) | 22/05/2013 | 20/03/2013 | A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) | A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis | Focal segmental glomerulosclerosis MedDRA version: 15.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Not possible to specify | Product Name: Fresolimumab Product Code: GC1008 INN or Proposed INN: Fresolimumab Other descriptive name: GZ402669 | Genzyme Corporation | NULL | Not Recruiting | Female: yes Male: yes | 125 | Phase 2 | France;United States;Brazil;Spain;Germany;Italy | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 141 | EUCTR2012-002365-35-ES (EUCTR) | 19/04/2013 | 09/04/2013 | A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) | A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis | Focal segmental glomerulosclerosis MedDRA version: 14.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Not possible to specify | Product Name: Fresolimumab Product Code: GC1008 INN or Proposed INN: Fresolimumab Other descriptive name: GZ402669 | Genzyme Corporation | NULL | Not Recruiting | Female: yes Male: yes | 125 | Phase 2 | France;United States;Brazil;Spain;Germany;Italy | ||
| 142 | NCT01762852 (ClinicalTrials.gov) | April 2013 | 4/1/2013 | Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy | BEL114674: A 2 Year Study of Efficacy and Safety of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy | Glomerulonephritis, Membranous | Drug: Belimumab 10 mg;Drug: Placebo | GlaxoSmithKline | NULL | Withdrawn | 18 Years | 75 Years | All | 0 | Phase 2 | United States;Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom |
| 143 | EUCTR2011-000242-38-CZ (EUCTR) | 14/02/2013 | 13/11/2012 | A 2 year study to investigate belimumab in membranous nephropathy | BEL114674: A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy - GSK1550188 in membranous nephropathy | Idiopathic Membranous Nephropathy (IMN) MedDRA version: 14.1;Level: SOC;Classification code 10038359;Term: Renal and urinary disorders;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: BENLYSTA® Product Name: BENLYSTA® Product Code: GSK1550188 (Belimumab) INN or Proposed INN: BELIMUMAB | GlaxoSmithKline Research & Development Ltd | NULL | Not Recruiting | Female: yes Male: yes | 94 | United States;France;Czech Republic;Canada;Spain;Australia;Netherlands;Germany;United Kingdom;Italy | |||
| 144 | EUCTR2011-000242-38-DE (EUCTR) | 09/01/2013 | 25/09/2012 | A 2 year study to investigate belimumab in membranous nephropathy | BEL114674: A 2 year study of efficacy and safety ofintravenous belimumab versus placebo in subjects withidiopathic membranous nephropathy - GSK1550188 in membranous nephropathy | Idiopathic Membranous Nephropathy (IMN) MedDRA version: 16.0;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: BENLYSTA® Product Name: BENLYSTA® Product Code: GSK1550188 (Belimumab) INN or Proposed INN: BELIMUMAB | GlaxoSmithKline Research & Development Ltd | NULL | Not Recruiting | Female: yes Male: yes | 94 | France;United States;Czech Republic;Canada;Spain;Australia;Netherlands;Germany;Italy;United Kingdom | |||
| 145 | NCT01791686 (ClinicalTrials.gov) | January 2013 | 29/1/2013 | Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease | A Pilot, Open-label, Multicenter Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease | Dense Deposit Disease;Membranoproliferative Glomerulonephritis Type II;C3 Glomerulonephritis | Drug: CDX-1135 | Celldex Therapeutics | NULL | Terminated | 4 Years | N/A | Both | 1 | Phase 1 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 146 | EUCTR2011-000242-38-ES (EUCTR) | 20/12/2012 | 22/10/2012 | A 2 year study to investigate belimumab in membranous nephropathy | A 2 year study of efficacy and safety ofintravenous belimumab versus placebo in subjects withidiopathic membranous nephropathy - GSK1550188 in membranous nephropathy | Idiopathic Membranous Nephropathy (IMN) MedDRA version: 14.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: BENLYSTA® Product Name: BENLYSTA® Product Code: GSK1550188 (Belimumab) INN or Proposed INN: BELIMUMAB | GlaxoSmithKline, S.A. | NULL | Not Recruiting | Female: yes Male: yes | 94 | United States;France;Czech Republic;Canada;Spain;Netherlands;Germany;United Kingdom;Italy | |||
| 147 | EUCTR2011-000242-38-IT (EUCTR) | 22/11/2012 | 11/12/2012 | A 2 year study to investigate belimumab in membranous nephropathy | A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy | Idiopathic Membranous Nephropathy (IMN) MedDRA version: 14.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: BENLYSTA INN or Proposed INN: BELIMUMAB | GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD. | NULL | Not Recruiting | Female: yes Male: yes | 94 | United States;Czech Republic;Canada;Spain;Germany;United Kingdom;Italy | |||
| 148 | EUCTR2011-000242-38-GB (EUCTR) | 01/11/2012 | 03/10/2012 | A 2 year study to investigate belimumab in membranous nephropathy | BEL114674: A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy - GSK1550188 in membranous nephropathy | Idiopathic Membranous Nephropathy (IMN) MedDRA version: 15.0;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | GlaxoSmithKline Research & Development Ltd | NULL | Not Recruiting | Female: yes Male: yes | 94 | Phase 2 | France;United States;Czech Republic;Canada;Spain;Netherlands;Germany;Italy;United Kingdom | |||
| 149 | JPRN-UMIN000008919 | 2012/09/15 | 14/09/2012 | The prospective multi-center study on the efficacy and safety of mizoribine for the treatment of aged nephrotic patients with primary membranous nephropathy. | The patients with nephrotic syndrome due to primary membranous nephropathy. | Treatment with a combination of mizoribine plus steroid therapy Treatment with steroid monotherapy | The study group of treatment for aged patients with nephrotic syndrome. | NULL | Complete: follow-up complete | 65years-old | Not applicable | Male and Female | 200 | Not applicable | Japan | |
| 150 | NCT01665391 (ClinicalTrials.gov) | August 2012 | 13/8/2012 | A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) | A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis | Primary Focal Segmental Glomerulosclerosis | Drug: fresolimumab;Drug: Placebo | Genzyme, a Sanofi Company | NULL | Completed | 18 Years | N/A | Both | 36 | Phase 2 | United States;Brazil;Germany;Italy;Spain |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 151 | NCT01763580 (ClinicalTrials.gov) | July 16, 2012 | 6/12/2012 | A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome | Open-Label, Randomized, Comparative, Multi-Center Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf Cap.®) in Combination With Low-Dose Corticosteroid Compared With High-Dose Corticosteroid Alone in Patients With Minimal-Change Nephrotic Syndrome (MCNS) | MCNS;Minimal Change Nephrotic Syndrome (MCNS) | Drug: Tacrolimus;Drug: Prednisolone | Astellas Pharma Korea, Inc. | NULL | Completed | 16 Years | 78 Years | All | 144 | Phase 4 | Korea, Republic of |
| 152 | EUCTR2011-006115-59-IT (EUCTR) | 11/06/2012 | 08/06/2012 | A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN) | A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN) - GNM-2011 | MN is an autoimmune disease, suggesting that the disease may be triggered by isotype specific autoantibodies directed against podocyte enzymes and podocyte receptors that are recognized as antigens. The key role of IgG antibodies formation in the pathogenesis of IMN suggests that B cell depletion may favourably impact the evolution of the glomerular disease and reduce proteinuria. We propose this study in order to test in a randomized controlled trial the hyp MedDRA version: 14.1;Level: PT;Classification code 10018372;Term: Glomerulonephritis membranous;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | Trade Name: MABTHERA*EV 1FL 50ML 500MG Trade Name: URBASON*IM EV 1F 250MG+1F 5ML Trade Name: MEDROL*10CPR DIV 4MG Trade Name: ENDOXAN BAXTER*50CPR RIV 50MG | AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy | ||||
| 153 | EUCTR2012-000385-38-GB (EUCTR) | 18/05/2012 | 02/04/2012 | A study to investigate belimumab in IMGN | BEL116472. A 2 year mechanistic study of belimumab in Idiopathic Membranous Glomerulonephropathy | Idiopathic Membranous Glomerulonephropathy (IMGN) MedDRA version: 16.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | GlaxoSmithKline Research and Development Ltd | NULL | Not Recruiting | Female: yes Male: yes | 18 | Phase 2 | United Kingdom | |||
| 154 | NCT01164098 (ClinicalTrials.gov) | February 2012 | 15/7/2010 | Rituximab to Prevent Recurrence of Proteinuria | The Use of Rituximab to Prevent Recurrence of Proteinuria in Patients Receiving Kidney Transplant for FSGS | FSGS;Proteinuria | Drug: Rituximab | George W. Burke | Genentech, Inc.;National Institutes of Health (NIH);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Terminated | 7 Years | 65 Years | All | 30 | Phase 3 | United States |
| 155 | ChiCTR-INR-15007440 | 2012-01-01 | 2015-10-30 | Multitarget Therapy for Treatment of Refractory idiopathic membranous nephropathy | Multitarget Therapy for Treatment of Refractory idiopathic membranous nephropathy | idiopathic membranous nephropathy | 1:Pred 1mg/kg+MMF 0.5Q12h+FK506 2mg Q12h ;2:Pred 1mg/kg+FK506 2mg Q12h;3:Pred 1mg/kg+CTX50mg BID; | The first affiliated hospital of Zhengzhou University | NULL | Recruiting | 18 | 65 | Both | 1:50;2:50;3:50; | China | |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 156 | NCT01508468 (ClinicalTrials.gov) | January 2012 | 9/12/2011 | Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy | Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy (IMN) | Idiopathic Membranous Nephropathy | Drug: symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin);Drug: experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab) | Assistance Publique - Hôpitaux de Paris | NULL | Active, not recruiting | 18 Years | N/A | Both | 80 | Phase 3 | France |
| 157 | NCT03018535 (ClinicalTrials.gov) | January 2012 | 9/1/2017 | Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy | A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy | Glomerulonephritis, Membranous | Drug: Rituximab;Drug: Methylprednisolone;Drug: Cyclophosphamide | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | University of Bari;Azienda Ospedaliera Brotzu;University of Messina;University of Milan;Universita di Verona;University of Chieti;University of Bologna;Azienda Sanitaria Locale Roma E;Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi;Regione Piemonte;University of Modena and Reggio Emilia;University of Pisa;University of Milano Bicocca;Humanitas Hospital, Italy;Azienda Ospedaliera Universitaria Policlinico;Fondazione Salvatore Maugeri;University of Bern;University of Alberta;Istituto Giannina Gaslini | Active, not recruiting | 18 Years | N/A | All | 76 | Phase 3 | Italy |
| 158 | NCT01180036 (ClinicalTrials.gov) | November 2011 | 10/8/2010 | MEmbranous Nephropathy Trial Of Rituximab | A Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN) | Idiopathic Membranous Nephropathy | Drug: Rituximab;Drug: Cyclosporine | Mayo Clinic | Columbia University;University of British Columbia;Ohio State University;Stanford University;University of Washington;University of Michigan;University of Alabama at Birmingham;Case Western Reserve University;The Cleveland Clinic;University of Kansas Medical Center;University of Manchester;University Health Network, Toronto;University of Toronto;CHU de Quebec-Universite Laval;Washington University School of Medicine;Florida International University;University of Mississippi Medical Center;NYU Langone Health;Medical College of Wisconsin;University of Arizona;Sunnybrook Health Sciences Centre;Applied Health Research Centre;Fulk Family Foundation | Completed | 18 Years | 80 Years | All | 130 | Phase 2;Phase 3 | United States;Canada |
| 159 | NCT01845688 (ClinicalTrials.gov) | November 2011 | 29/4/2013 | Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy | Efficacy and Safety Evaluation of QingReMoShen Granule in the Treatment of Idiopathic Membranous Nephropathy : A Randomized Double-Blind Controlled Clinical Study | Idiopathic Membranous Nephropathy | Drug: Losartan Tablets & QingReMoShen Granule;Drug: Losartan Tablets & Placebo Granule | wanglin | NULL | Active, not recruiting | 18 Years | 70 Years | Both | 72 | N/A | China |
| 160 | NCT01451489 (ClinicalTrials.gov) | October 13, 2011 | 5/8/2011 | The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis | A Randomized,Multicentre,Prospective Study on the Tacrolimus(FK506)for Focal Segmental Glomerulosclerosis | FSGS | Drug: FK506;Drug: Cyclophosphamide | Nanjing University School of Medicine | NULL | Terminated | 14 Years | 65 Years | All | 70 | N/A | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 161 | ChiCTR-TRC-11001454 | 2011-08-01 | 2011-08-08 | Tacrolimus monotherapy follows intravenous methylprednisolone in adults with minimal change nephrotic syndrome: a prospective, multi-centered, open, randomized, controlled trial | Tacrolimus monotherapy follows intravenous methylprednisolone in adults with minimal change nephrotic syndrome: a prospective, multi-centered, open, randomized, controlled trial | minimal change disease in adults;ICD10:N04.001 | Group A:Tacrolimus orally taken 0.5-1mg q12h for 36w, tape;Group B:prednisone orally taken for 36w, 1.0 mg/kg.d, tape; | Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University | NULL | Completed | Both | Group A:60;Group B:60; | China | |||
| 162 | NCT01386554 (ClinicalTrials.gov) | August 2011 | 29/6/2011 | Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients | A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN) | Proteinuria;Idiopathic Membranous Nephropathy | Drug: Repository Corticotropin Injection;Drug: Placebo | Mallinckrodt | NULL | Completed | 18 Years | N/A | All | 60 | Phase 4 | United States;Canada;Chile;Mexico;Turkey |
| 163 | JPRN-UMIN000005231 | 2011/03/01 | 10/03/2011 | Uncontrol trial of rituximab treatment on steroid dependent and frequently relapsing minimal cahnge nephrotic syndrome(MCNS) | steroid dependent and frequently relapsing minimal change nephrotic syndrome | rituximab 375mg/m2 single-dose 1 time/6months 24 months follow up | Department of Medicine, Kidney Center, Tokyo Women's Medical University | NULL | Complete: follow-up complete | 20years-old | 60years-old | Male and Female | 50 | Phase 3 | Japan | |
| 164 | NCT01282073 (ClinicalTrials.gov) | March 2011 | 19/1/2011 | Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy | A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy | Glomerulonephritis, Membranous | Drug: Mycophenolate mofetil, low dose steroid;Drug: Cyclosporin, low dose steroid | Kyungpook National University | Hanmi Pharmaceutical Company Limited | Recruiting | 18 Years | N/A | Both | 62 | Phase 3 | Korea, Republic of |
| 165 | NCT00977977 (ClinicalTrials.gov) | December 2, 2010 | 15/9/2009 | Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy | Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy | Nephrotic Syndrome;Proteinuria;Autoimmune Disease;Glomerular Disease;Membranous Glomerulonephritis | Drug: Rituximab Infusion;Drug: Oral Cyclosporine | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NULL | Recruiting | 18 Years | 100 Years | All | 30 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 166 | NCT01799460 (ClinicalTrials.gov) | December 2010 | 8/1/2013 | Study on Single-nucleotide-polymorphism in Idiopathic Membranous Nephropathy | Mechanism Research of Traditional Chinese Medicine (the Comprehensive Treatment Regimen) in Treating Idiopathic Membranous Nephropathy by Genomewide Association Studies | Idiopathic Membranous Nephropathy | Drug: The Comprehensive Treatment Regimen of Traditional Chinese Medicine;Drug: The immunosuppressive agents | Shanghai University of Traditional Chinese Medicine | NULL | Recruiting | 18 Years | 70 Years | Both | 80 | N/A | China |
| 167 | NCT01093781 (ClinicalTrials.gov) | November 2010 | 24/3/2010 | Aliskiren in Patients With Idiopathic Membranous Nephropathy | A Pilot Study to Evaluate the Antiproteinuric Effect of Renin Inhibition With Aliskiren in Patients With Idiopathic Membranous Nephropathy | Idiopathic Membranous Nephropathy | Drug: Aliskiren | Mayo Clinic | NULL | Withdrawn | 18 Years | 80 Years | Both | 0 | N/A | United States |
| 168 | ChiCTR-TRC-10000871 | 2010-09-01 | 2010-05-21 | A randomized post-market trial of Huang Qi Huai for chilhood steroid-sensitive nephrotic syndrome | A randomized post-market trial of Huang Qi Huai for chilhood steroid-sensitive nephrotic syndrome | Steroid-sensitive primary nephrotic syndrome in children | Group A:Prednisolone (tablets) + Huai Qi Huang (particle);Group B:Prednisolone (tablets) + placebo (particle); | Children's Hospital Affiliated to Fudan UniversityNanjing Children's Hospital | NULL | Completed | 1 | 12 | Both | Group A:50;Group B:50; | China | |
| 169 | NCT01185197 (ClinicalTrials.gov) | September 2010 | 13/8/2010 | Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study | Myfortic® Combined With Low-dose Steroid in Minimal Change Nephrotic Syndrome | Nephrosis, Lipoid | Drug: Myfortic plus low-dose steroid;Drug: Prednisolone | The University of Hong Kong | NULL | Completed | 18 Years | 65 Years | All | 20 | Phase 4 | China |
| 170 | NCT01162005 (ClinicalTrials.gov) | July 2010 | 12/7/2010 | Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in Children | Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in Children | Nephrotic Syndrome | Drug: Tacrolimus | Seoul National University Hospital | Chong Kun Dang Pharmaceutical | Completed | N/A | 18 Years | All | 77 | Phase 4 | Korea, Republic of |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 171 | NCT01221181 (ClinicalTrials.gov) | July 2010 | 13/10/2010 | Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy | Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy | Dense Deposit Disease;Membranoproliferative Glomerulonephritis | Drug: Eculizumab | Columbia University | Alexion Pharmaceuticals | Completed | 18 Years | N/A | All | 6 | Phase 1 | United States |
| 172 | NCT01161459 (ClinicalTrials.gov) | June 2010 | 12/7/2010 | Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid | Research Institute of Nephrology, Jinling Hospital | Idiopathic Membranous Nephropathy | Drug: Tripterygium wilfordii;Drug: FK506 | Zhi-Hong Liu, M.D. | NULL | Completed | 18 Years | 65 Years | Both | 100 | N/A | China |
| 173 | EUCTR2009-016003-26-GB (EUCTR) | 06/05/2010 | 17/03/2010 | RANDOMISED PILOT TRIAL OF MYFORTIC FOR THE TREATMENT OF PRIMARY PROTEINURIC GLOMERULONEPHRITIS. - GloMY - Proteinuria in glomerulonephritis : Myfortic | RANDOMISED PILOT TRIAL OF MYFORTIC FOR THE TREATMENT OF PRIMARY PROTEINURIC GLOMERULONEPHRITIS. - GloMY - Proteinuria in glomerulonephritis : Myfortic | Primary Proteinuric Glomeruolnephritis Focal segmental glomeruloscerosis and IgA nephropathy MedDRA version: 14.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders | Trade Name: Myfortic Product Name: Myfortic 360mg Tablets INN or Proposed INN: mycophenolic acid Other descriptive name: mycophenolate sodium Trade Name: Myfortic Product Name: Myfortic 180mg Tablets INN or Proposed INN: mycophenolic sodium Other descriptive name: mycophenolate sodium Product Name: Prednisolone INN or Proposed INN: prednisolone | UHB NHS Foundation Trust | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | United Kingdom | ||
| 174 | NCT01093157 (ClinicalTrials.gov) | February 2010 | 24/3/2010 | A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy | A Dose-finding Pilot Study of ACTH (Adrenocorticotropic Hormone) on the Proteinuria and Serum Lipoprotein Profile in Patients With Idiopathic Membranous Nephropathy (MN) | Glomerulonephritis | Drug: Adrenocorticotrophic hormone ACTH | University Health Network, Toronto | Mallinckrodt | Completed | 18 Years | 72 Years | All | 10 | Phase 1;Phase 2 | Canada |
| 175 | ChiCTR-TQR-12002602 | 2009-10-09 | 2012-10-16 | The Effects of an Combinedative Treatment of with Prednisone plus and Fluvastatin on the Levels of Cholesterol and Bilirubin in the Patients with Minimal Change Nephropathy | The Effects of an Combinedative Treatment of with Prednisone plus and Fluvastatin on the Levels of Cholesterol and Bilirubin in the Patients with Minimal Change Nephropathy | Minimal change nephrotic syndrome in children | Treatment:prednisone 1~2 mg/kg/day+Fluvastatin Sodium Capsule;Control:prednisone 1~2 mg/kg/day; | Treatment center of kidney disease, 281th hospital of PLA | NULL | Completed | 4 | 12 | Both | Treatment:30;Control:30; | I (Phase 1 study) | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 176 | NCT01197040 (ClinicalTrials.gov) | October 2009 | 7/9/2010 | Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome | Low Steroid Dose Combined With Mycophenolic Acid (Myfortic) Compared With High Dose Steroid for Minimal Change Nephrotic Syndrome | Nephrotic Syndrome | Drug: Prednisone;Drug: acid mycophenolic (Myfortic) | Assistance Publique - Hôpitaux de Paris | Novartis | Completed | 18 Years | N/A | All | 117 | Phase 3 | France |
| 177 | NCT01113385 (ClinicalTrials.gov) | October 2009 | 28/4/2010 | Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome | Effect of Oral Galactose on the Level of Focal Sclerosis Permeability Factor and Proteinuria in Children With Steroid Resistant Nephrotic Syndrome: A Pilot Study | Focal Segmental Glomerulosclerosis;Steroid Resistant Nephrotic Syndrome | Drug: D-Galactose | Children's Research Institute | National Kidney Foundation | Completed | 2 Years | 21 Years | All | 7 | N/A | United States |
| 178 | NCT01129557 (ClinicalTrials.gov) | September 2009 | 21/5/2010 | Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease | Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease | Proteinuric Kidney Disease;Diabetic Nephropathy;Hypertensive Nephrosclerosis;IgA Nephropathy;Focal Segmental Glomerulosclerosis;Glomerulopathy (Obesity-associated);Glomerulonephritis, Membranous | Drug: Aliskiren;Drug: Valsartan | Columbia University | Novartis Pharmaceuticals | Terminated | 18 Years | N/A | All | 46 | Phase 4 | United States |
| 179 | NCT01155141 (ClinicalTrials.gov) | September 2009 | 29/6/2010 | Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH | Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH | Kidney Diseases | Drug: H.P. Acthar Gel | Stanford University | Mallinckrodt | Completed | 16 Years | 65 Years | All | 15 | Phase 4 | United States |
| 180 | NCT00956059 (ClinicalTrials.gov) | September 2009 | 10/8/2009 | Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis | Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis | Focal Segmental Glomerulosclerosis | Drug: prednisone, FK506, MMF;Drug: prednisone | Xi’an Jiaotong University College of Medicine | NULL | Not yet recruiting | 16 Years | 70 Years | Both | 40 | N/A | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 181 | EUCTR2008-006750-17-IT (EUCTR) | 14/04/2009 | 27/01/2009 | A prospective, sequential study to assess the efficacy of rituximab therapy in maintaining remission of nephrotic syndrome after steroid and immunosuppressive therapy withdrawal in patients with steroid-dependant or multirelapsing minimal change disease or focal segmental glomerulosclerosis - NEMO | A prospective, sequential study to assess the efficacy of rituximab therapy in maintaining remission of nephrotic syndrome after steroid and immunosuppressive therapy withdrawal in patients with steroid-dependant or multirelapsing minimal change disease or focal segmental glomerulosclerosis - NEMO | Nephrotic Syndrome secondary to minimal change disease (MCD) or idiopathic focal and segmental glomerulosclerosis (FSGS. MedDRA version: 9.1;Level: LLT;Classification code 10029171 MedDRA version: 9.1;Classification code 10058326 MedDRA version: 9.1;Classification code 10016832 | IST. DI RICERCHE FARMACOLOG. M. NEGRI | NULL | Not Recruiting | Female: yes Male: yes | 20 | Phase 3 | Italy | |||
| 182 | NCT00981838 (ClinicalTrials.gov) | April 2009 | 21/9/2009 | Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS) | A Prospective, Sequential Study to Assess the Efficacy of Rituximab Therapy in Maintaining Remission of Nephrotic Syndrome After Steroid and Immunosuppressive Therapy Withdrawal in Patients With Steroid-dependant or Multirelapsing Minimal Change Disease or Focal Segmental Glomerulosclerosis (NEMO Study) | Nephrotic Syndrome | Drug: Rituximab | Mario Negri Institute for Pharmacological Research | Agenzia Italiana del Farmaco | Completed | 2 Years | 80 Years | Both | 24 | Phase 3 | Italy |
| 183 | ChiCTR-ONC-12002809 | 2009-01-01 | 2012-05-24 | Clinical Study of Prediction of Glucocorticoid Efficacy by cytokins in Patients with Primary Nephrotic Syndrome | Clinical Study of Prediction of Glucocorticoid Efficacy by cytokins in Patients with Primary Nephrotic Syndrome | Idiopathic nephrotic syndrome | 1:Given methylprednisolone according to the status of the patients ; | The First Affiliated Hospital of Dalian Medical University | NULL | Completed | 18 | 75 | Both | 1:90; | China | |
| 184 | NCT00805753 (ClinicalTrials.gov) | January 2009 | 9/12/2008 | Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy | A Dose-Finding Pilot Study of ACTH on the Serum Lipoprotein Profile and Proteinuria in Patients With Idiopathic Membranous Nephropathy (MN) | Idiopathic Membranous Nephropathy | Drug: ACTH | Mayo Clinic | Questcor Pharmaceuticals, Inc. | Completed | 18 Years | N/A | Both | 20 | Phase 1 | United States;Canada |
| 185 | NCT00801463 (ClinicalTrials.gov) | January 2009 | 2/12/2008 | Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis | Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis | Proteinuria;Focal Segmental Glomerulosclerosis | Drug: tripterygium wilfordii (TW) | Nanjing University School of Medicine | NULL | Completed | 18 Years | 60 Years | Both | 67 | N/A | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 186 | NCT00816504 (ClinicalTrials.gov) | December 2008 | 31/12/2008 | Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5 | Effect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS)and Chronic Kidney Disease Stage 5 | Focal Segmental Glomerulosclerosis | Drug: Galactose | North Shore Long Island Jewish Health System | Medical College of Wisconsin | Withdrawn | 2 Years | 60 Years | Both | 0 | Phase 1 | United States |
| 187 | NCT00814255 (ClinicalTrials.gov) | December 2008 | 22/12/2008 | Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial | Novel Therapies for Resistant Focal Segmental Glomerulosclerosis | Focal Segmental Glomerulosclerosis | Drug: Adalimumab;Drug: Lisinopril, losartan, and atorvastatin;Drug: galactose | New York University School of Medicine | University of Michigan;The Cleveland Clinic;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | 1 Year | 65 Years | All | 32 | Phase 2 | United States;Canada |
| 188 | NCT00816478 (ClinicalTrials.gov) | December 2008 | 31/12/2008 | Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor | Effect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS) | Focal Segmental Glomerulosclerosis | Drug: Galactose | North Shore Long Island Jewish Health System | NULL | Terminated | 2 Years | 60 Years | Both | 15 | Phase 1 | United States |
| 189 | NCT00694863 (ClinicalTrials.gov) | July 2008 | 9/6/2008 | Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy | Treatment With Synthetic Adrenocorticotropic Hormone (ACTH) in Patients With Membranous Nephropathy and High Risk for Renal Failure. A Pilot Study | Idiopathic Membranous Nephropathy | Drug: tetracosactide hexacetaat | Radboud University | Dutch Kidney Foundation | Completed | 18 Years | 95 Years | Both | 20 | Phase 2 | Netherlands |
| 190 | EUCTR2007-005410-39-ES (EUCTR) | 11/06/2008 | 08/04/2008 | Estudio piloto aleatorizado comparativo de tacrolimus vs ciclofosfamida-prednisona en la nefropatía membranosa idiopática” - MEMTAC | Estudio piloto aleatorizado comparativo de tacrolimus vs ciclofosfamida-prednisona en la nefropatía membranosa idiopática” - MEMTAC | La nefropatía membranosa idiopática (NMI) es una enfermedad caracterizada histopatológicamente por un engrosamiento uniforme de la pared de los capilares glomerulares, debido al depósito de complejos inmunes a lo largo del espacio subepitelial, en ausencia de inflamación o cambios proliferativos en el resto del glomérulo. El origen exacto de este trastorno se desconoce sin embargo se sabe que la NMI es una causa frecuente de síndrome nefrótico (SN) del adulto. MedDRA version: 9.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy | Trade Name: Advagraf 0,5mg INN or Proposed INN: tacrolimus Trade Name: Genoxal INN or Proposed INN: ciclofosfamida Trade Name: Dacortín 2,5mg INN or Proposed INN: prednisona Trade Name: Advagraf 1mg INN or Proposed INN: tacrolimus Trade Name: Advagraf 5mg INN or Proposed INN: tacrolimus Trade Name: Dacortín 5mg INN or Proposed INN: prednisona Trade Name: Dacortín 30mg INN or Proposed INN: prednisona | Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 40 | Spain | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 191 | EUCTR2008-001647-19-NL (EUCTR) | 22/05/2008 | 04/06/2008 | Treatment with synthetic adrenocoticotropic hormone (ACTH) in patients with membranous nephropathy and high risk for renal failure. A pilot study. - ACTHiMeN | Treatment with synthetic adrenocoticotropic hormone (ACTH) in patients with membranous nephropathy and high risk for renal failure. A pilot study. - ACTHiMeN | Membranous nephropathy MedDRA version: 9.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy | Trade Name: Synacthen Depot 1mg | Radboud University Nijmegen Medical Center | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands | ||||
| 192 | ChiCTR-TRC-08000098 | 2008-04-01 | 2008-04-14 | Reseaech on integrated therapy of traditional Chinese medicine for membranous nephropathy | Reseaech on integrated therapy of traditional Chinese medicine for membranous nephropathy | Idiopathic membranous nephropathy | Treatment group:Integrated therapy of TCM;Control group:Prednisone and CTX; | Longhua Hospital Affiliated to Shanghai University of TCM | NULL | Completed | 18 | 75 | Both | Treatment group:95;Control group:95; | I (Phase 1 study) | China |
| 193 | NCT00782561 (ClinicalTrials.gov) | April 2008 | 27/10/2008 | Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS) | A Phase I, Open-Label Study of the Safety and Pharmacokinetics of FG-3019 in Adolescent and Adult Subjects With Steroid-Resistant Focal Segmental Glomerulosclerosis | Focal Segmental Glomerulosclerosis | Drug: FG-3019 | FibroGen | NULL | Terminated | 12 Years | 64 Years | All | 2 | Phase 1 | United States |
| 194 | ChiCTR-TRC-10001024 | 2008-01-01 | 2010-09-14 | Tacrolimus versus Cyclophosphamide for Therapy in steroid-resistant and steroid-dependent primary focal segmental glomerulosclerosis | Tacrolimus versus Cyclophosphamide for Therapy in steroid-resistant and steroid-dependent primary focal segmental glomerulosclerosis | primary focal segmental glomerulosclerosis | group A:intravenous CTX 0.5-0.75g/m2 Monthly+Oral prednisone (Prednisolone) 0.8mg/kg.d ;group B:Oral FK506 FK506 0.1mg/kg.d+prednisone (Prednisolone) 0.5mg/kg.d ; | Shanghai Jiaotong University Affiliated Ruijin Hospital | NULL | Completed | 18 | 75 | Both | group A:30;group B:30; | China | |
| 195 | NCT00550342 (ClinicalTrials.gov) | January 2008 | 26/10/2007 | Rituximab Treatment of Focal Segmental Glomerulosclerosis | Anti-CD20, Rituximab, for the Treatment of Recurrent or Primary Resistant Focal Segmental Glomerulosclerosis (FSGS) | Focal Segmental Glomerulosclerosis (FSGS) | Drug: rituximab | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Genentech, Inc.;Indiana University | Completed | 5 Years | 60 Years | All | 10 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 196 | JPRN-UMIN000001099 | 2007/10/01 | 31/03/2008 | Optimal use of ciclosporin in idiopathic membranous nephropathy associated with nephrotic syndrome | idiopathic membranous nephropathy associated with nephrotic syndrome | Steroid group: Immunosuppressive therapy is started by predonisolone 0.8mg/kg/day (max 60mg/day). The dose is decreased by 5mg/day in 2 to 4 weeks after remission. The cases who do not reach remission for 4 weeks, predonisolone is decreased to 0.6mg/kg/day, and ciclosporin (2mg/kg/day) is started once a day. Serum concentration of ciclosporin is measured 2hr after administration, and the dose is adjusted. (The target serum concentration is 800-1000ng/mL.) Steroid + ciclosporin group: Immunosupressive therapy is started by predonisolone 0.6mg/kg/day and ciclosporin 2mg/kg/day (once a day). Serum concentration of ciclosporin is measured 2hr after administration, and the dose is adjusted. (The target serum concentration is 800-1000ng/mL.) The dose of predonisolone is decreased by 5mg/day in 2 to 4 weeks after remission. Ciclosporin is continued after remission. (The target C2 is 600-800 ng/mL.) The cases who do not reach remission after 4 weeks, predonisolone is decreased by 5mg/4-8week, and ciclosporin is continued for 6 months. The target C2 is 800-1000ng/mL. At 6 months after, the therapy of non-respnder is not restricted. | Division of Kidney and Dialysis, Department of Internal Medicine,Hyogo College of Medicine | NULL | 16years-old | Not applicable | Male and Female | 50 | Phase 4 | Japan | ||
| 197 | JPRN-UMIN000000963 | 2007/10/01 | 01/01/2010 | Efficacy and safety of cyclosporine and steroid for the treatment of minimal change nephrotic syndrome | Minimal change nephrotic syndrome | administration of cyclosporine | Yoshihiko Saito | NULL | Complete: follow-up complete | 20years-old | 75years-old | Male and Female | 30 | Not applicable | Japan | |
| 198 | NCT00479622 (ClinicalTrials.gov) | August 2007 | 25/5/2007 | Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus | A Randomized, Two-Arm, Parallel Group Study of the Safety, Pharmacokinetics, and Pharmacodynamics of TRU-015 Added to Standard Therapy in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Drug: TRU-015 | Wyeth is now a wholly owned subsidiary of Pfizer | Emergent Product Development Seattle LLC | Terminated | 18 Years | 70 Years | Both | 20 | Phase 1 | United States |
| 199 | NCT00518219 (ClinicalTrials.gov) | July 2007 | 16/8/2007 | To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN) | To Compare the Efficacy and Safety of TW vs Valsartan in the MN | Membranous Nephropathy | Drug: TW | Nanjing University School of Medicine | NULL | Completed | 18 Years | 65 Years | Both | 68 | Phase 4 | China |
| 200 | NCT00464321 (ClinicalTrials.gov) | May 2007 | 20/4/2007 | Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS | A Phase I, Multicentre, Open-label, Dose-escalating Study of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS) | Focal Segmental Glomerulosclerosis | Biological: GC1008 | Genzyme, a Sanofi Company | NULL | Completed | 18 Years | N/A | Both | 16 | Phase 1 | United States;Germany;Italy;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 201 | JPRN-UMIN000000621 | 2007/03/01 | 28/02/2007 | Okayama nephrotic syndrome treatment group: Study group for short-term combination therapy of angiotensin-2 receptor blocker and cyclosporine for keeping remission | Minimal change nephrotic syndrome | Prednisolone (+), combination therapy (-) Prednisolone (+), combination therapy (+) | Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan | NULL | Complete: follow-up complete | 16years-old | Not applicable | Male and Female | 50 | Not selected | Japan | |
| 202 | NCT00405340 (ClinicalTrials.gov) | October 2006 | 29/11/2006 | Rituximab in the Treatment of Idiopathic Membranous Nephropathy | Rituximab in the Treatment of Idiopathic Membranous Nephropathy | Membranous Nephropathy | Drug: Rituximab | Mayo Clinic | Genentech, Inc. | Completed | 18 Years | N/A | Both | 20 | Phase 0 | United States |
| 203 | NCT00354731 (ClinicalTrials.gov) | August 2006 | 18/7/2006 | Efficacy of Pentoxifylline on Primary Nephrotic Syndrome | Clinical Efficacy of Pentoxifylline on Patients With Primary Nephrotic Syndrome | Nephrotic Syndrome | Drug: pentoxifylline;Drug: Corticosteroid | National Taiwan University Hospital | National Science Council, Taiwan | Completed | 20 Years | 80 Years | Both | 62 | Phase 3 | Taiwan |
| 204 | ChiCTR-OPN-17012789 | 2006-06-01 | 2017-09-25 | Glucocorticoids in the treatment of patients with primary focal segmental glomerulosclerosis and moderate proteinuria | Glucocorticoids in the treatment of patients with primary focal segmental glomerulosclerosis and moderate proteinuria | focal segmental glomerulosclerosis | study group:prednisone treatment;control group:ACEI/ARB; | Institute of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | NULL | Completed | 17 | 80 | Both | study group:52;control group:50; | China | |
| 205 | EUCTR2005-004469-40-BE (EUCTR) | 12/05/2006 | 05/12/2005 | Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to ACE-inhibitors alone in the treatment of de novo nephrotic syndrome due to idiopathic membranous glomerulopathy | Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to ACE-inhibitors alone in the treatment of de novo nephrotic syndrome due to idiopathic membranous glomerulopathy | Membranous Nephropathy | Trade Name: Neoral Product Name: Neoral Trade Name: zestril Product Name: zestril | Hopital Erasme | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Belgium | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 206 | EUCTR2005-004460-22-BE (EUCTR) | 12/05/2006 | 05/12/2005 | Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to corticosteroids with ACE-inhibitors in the treatment of de novo nephrotic syndrome due to focal segmental glomerulosclerosis. | Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to corticosteroids with ACE-inhibitors in the treatment of de novo nephrotic syndrome due to focal segmental glomerulosclerosis. | focal and segmental glomerulosclerosis | Trade Name: Neoral Product Name: Neoral Trade Name: Medrol Product Name: Medrol Trade Name: zestril Product Name: zestril | Hopital Erasme | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Belgium | |||
| 207 | JPRN-C000000158 | 2006/03/01 | 01/04/2006 | Mizoribin for primary nephrotic syndrome in children(JSRDC09) | Steroid-sensitive nephrotic syndrome | mizoribine+prednisolone | Japanese Study Group of Renal Disease in Children(JSRDC) | NULL | Complete: follow-up complete | 1years-old | 10years-old | Male and Female | 50 | Not selected | Japan | |
| 208 | NCT00302536 (ClinicalTrials.gov) | March 2006 | 13/3/2006 | Tacrolimus Treatment of Patients With Idiopathic Focal Segmental Glomerulosclerosis | Tacrolimus Treatment of Patients With Idiopathic Focal Segmental | Focal Glomerulosclerosis | Drug: Tacrolimus | Nanjing University School of Medicine | NULL | Withdrawn | 15 Years | 50 Years | Both | 0 | N/A | China |
| 209 | NCT00983034 (ClinicalTrials.gov) | March 2006 | 21/9/2009 | The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy | Prospective Study of the Effects of Helicobacter Pylori Eradication on Renal Functions and Proteinuria in Patients With Membranous Nephropathy | Nephrotic Syndrome;Glomerulonephritis;Membranous Nephropathy | Drug: lansoprazole, amoxicillin, clarithromycin | Istanbul University | NULL | Completed | 18 Years | 70 Years | Both | 70 | N/A | Turkey |
| 210 | NCT00302523 (ClinicalTrials.gov) | March 2006 | 13/3/2006 | Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy | Tacrolimus Treatment of Patients With Idiopathic | Idiopathic Membranous Nephropathy | Drug: Tacrolimus | Nanjing University School of Medicine | NULL | Completed | 18 Years | 60 Years | Both | 16 | N/A | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 211 | NCT00275613 (ClinicalTrials.gov) | November 2005 | 10/1/2006 | Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis | Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis | Glomerulonephritis, Membranoproliferative | Drug: Rituximab | Mayo Clinic | NULL | Completed | 18 Years | N/A | Both | 10 | Phase 1 | United States |
| 212 | NCT00193648 (ClinicalTrials.gov) | July 2005 | 10/9/2005 | Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS) | Novel Therapies for Resistant FSGS | Focal Glomerulosclerosis | Drug: Rosiglitazone (Avandia);Drug: Adalimumab (Humira) | North Shore Long Island Jewish Health System | University of North Carolina;The Cleveland Clinic | Completed | 2 Years | 40 Years | Both | 21 | Phase 1 | United States |
| 213 | JPRN-UMIN000004653 | 2005/01/01 | 02/12/2010 | The clinical effects and safty of cyclosporine with rootine corticosteroid treatment in onset MCNS | minimal change nephrotic syndrome | cyclosporine A 2-3mg/kg/day | Yokohama city university graduate school of medicine | NULL | Complete: follow-up continuing | 16years-old | Not applicable | Male and Female | 20 | Not applicable | Japan | |
| 214 | NCT00135811 (ClinicalTrials.gov) | November 2004 | 24/8/2005 | Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT) | Focal Segmental Glomerulosclerosis Clinical Trial | Glomerulosclerosis, Focal | Drug: Cyclosporin;Drug: MMF and Dexamethasone | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | The Cleveland Clinic | Completed | 2 Years | 40 Years | Both | 207 | Phase 3 | United States |
| 215 | NCT00362531 (ClinicalTrials.gov) | November 2004 | 9/8/2006 | Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome | Phase 3 Study of Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome | Idiopathic Membranous Nephropathy;Nephrotic Syndrome | Drug: tacrolimus combined with prednisone | Peking University | NULL | Completed | 18 Years | 70 Years | Both | Phase 2;Phase 3 | NULL | |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 216 | NCT00425217 (ClinicalTrials.gov) | August 2004 | 19/1/2007 | Rituximab in Membranous Nephropathy | The Use of Rituximab in the Treatment of Idiopathic Membranous Nephropathy | Membranous Nephropathy | Drug: Rituximab | Mayo Clinic | Genentech, Inc. | Completed | 18 Years | N/A | Both | 15 | Phase 2;Phase 3 | United States |
| 217 | ChiCTR1900022518 | 2004-04-01 | 2019-04-15 | Clinical trial for corticosteroids monotherapy in the treatment of seronegative hepatitis B virus-associated membranous nephropathy. | Efficacy and safety of corticosteroids in 26 cases of seronegative hepatitis B virus-associated membranous nephropathy | Seronegative Hepatitis B Virus-associated Membranous Nephropathy | Case series:give corticosteroids(Methylprednisolone); | Tianjin Hospital | NULL | Completed | Both | Case series:26; | China | |||
| 218 | JPRN-C000000369 | 2004/04/01 | 27/03/2006 | Multicenter study for combined therapy of prednisolone and cyclosporin in refractory nephrotic syndrome | membranouos nephropathy and focal segmental glomerulosclerosis with primary steroid resistant nephrotic syndrome | CyA-MEPC once a day per os administration at 3mg/kgBW for 48 weeks CyA-MEPC twice a day per os administration at total 3mg/kgBW for 48 weeks | Project team for treatment of refractory nephrotic syndrome | The Progressive Renal Disease Research Projects in the Ministry of Health, Labor and Welfare, Japan | Complete: follow-up complete | 16years-old | 75years-old | Male and Female | 300 | Not selected | Japan | |
| 219 | JPRN-C000000368 | 2004/04/01 | 27/03/2006 | Multicenter study for combined therapy of prednisolone and mizoribine in idiopathic membranous nephropathy with refractory nephrotic syndrome | membranous nephropathy with primary steroid resistant nephrotic syndrome | mizoribine once a day per os administration (150mg) after breakfast for 2years. mizoribine 3 times a day per os administration (50mg each) after meals for 2years. | Project team for treatment of refractory nephrotic syndrome | The Progressive Renal Disease Research Projects in the Ministry of Health, Labor and Welfare, Japan | Complete: follow-up complete | 16years-old | 75years-old | Male and Female | 100 | Not selected | Japan | |
| 220 | ChiCTR-TRC-09000539 | 2004-03-01 | 2009-09-30 | Clinical studies of tacrolimus in idiopathic membranous Nephropathy with nephrotic syndrome therapy | Clinical studies of tacrolimus in idiopathic membranous Nephropathy with nephrotic syndrome therapy | Nephrotic Disease | S:Patients receive tacrolimus combined with prednison for six months;L:Patients receive tacrolimus combined with prednison for 24 months; | Second Hospital of Jilin University | NULL | Completed | 16 | 69 | Both | S:10;L:10; | China | |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 221 | NCT00404833 (ClinicalTrials.gov) | January 2003 | 27/11/2006 | Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental | A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS) | Glomerulonephritis, Membranous;Glomerulosclerosis, Focal | Drug: prednisolone and mycophenolate mofetil;Drug: prednisolone and chlorambucil | Hospital Authority, Hong Kong | The University of Hong Kong | Completed | 18 Years | 65 Years | Both | 16 | Phase 3 | China |
| 222 | NCT00050713 (ClinicalTrials.gov) | December 17, 2002 | 17/12/2002 | Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy | Sirolimus Therapy in Idiopathic and Lupus Membranous Nephropathy | Membranous Glomerulonephritis;Lupus Membranous Nepropathy | Drug: Sirolimus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NULL | Completed | 13 Years | N/A | All | 12 | Phase 2 | United States |
| 223 | NCT00040508 (ClinicalTrials.gov) | June 2002 | 26/6/2002 | Sirolimus for Focal Segmental Glomerulosclerosis | Sirolimus for Focal Segmental Glomerulosclerosis | Focal Glomerulosclerosis | Drug: Sirolimus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NULL | Completed | N/A | N/A | Both | 30 | Phase 2 | United States |
| 224 | NCT00135967 (ClinicalTrials.gov) | May 2002 | 25/8/2005 | Mycophenolate Mofetil in Membranous Nephropathy | Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study | Glomerulonephritis, Membranous | Drug: mycophenolate mofetil orally 1000 mg twice a day (BID);Drug: prednisone 0,5 mg/kg orally on alternate days;Drug: intravenous (i.v.) methylprednisolone 1000 mg, total 9 | Radboud University | Hoffmann-La Roche | Completed | 18 Years | 75 Years | Both | 30 | Phase 2;Phase 3 | Netherlands |
| 225 | JPRN-C000000379 | 2001/04/01 | 01/04/2006 | Prednisolone only and a combination of prednisolone and mizoribine for primary nephrotic syndrome relapsed within six mounths after first onset in children: A randomized controlled trial of efficacy and safety (JSRDC06) | Steroid-sensitive nephrotic syndrome | prednisolone mizoribine+prednisolone | Japanese Study Group of Renal Disease in Children(JSRDC) | NULL | Complete: follow-up complete | 1years-old | 10years-old | Male and Female | 50 | Not selected | Japan | |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 226 | NCT00007475 (ClinicalTrials.gov) | December 2000 | 22/12/2000 | Permeability Factor in Focal Segmental Glomerulosclerosis | Permeability Factor in Focal Segmental Glomerulosclerosis | Focal Segmental Glomerulosclerosis | Procedure: Plasma exchange;Drug: Cyclophosphamide | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NULL | Completed | N/A | N/A | All | 15 | Phase 1;Phase 2 | United States |
| 227 | NCT00004990 (ClinicalTrials.gov) | March 2000 | 18/3/2000 | Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis | Pulse Dexamethasone in Focal Segmental Glomerulosclerosis | Glomerulonephritis;Nephrotic Syndrome | Drug: Dexamethasone | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NULL | Completed | N/A | N/A | Both | 20 | Phase 2 | United States |
| 228 | NCT00001959 (ClinicalTrials.gov) | December 1999 | 18/1/2000 | Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis) | Pirfenidone in Focal Segmental Glomerulosclerosis:Phase II Study | Fibrosis;Focal Glomerulosclerosis;Kidney Failure;Nephrotic Syndrome;Proteinuria | Drug: Pirfenidone | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NULL | Completed | 18 Years | N/A | All | 21 | Phase 2 | United States |
| 229 | NCT00135954 (ClinicalTrials.gov) | July 1997 | 25/8/2005 | Treatment of Patients With Idiopathic Membranous Nephropathy | Treatment of Patients With Idiopathic Membranous Nephropathy at Risk for Renal Insufficiency: Comparison of Early Versus Late Start of Immunosuppressive Therapy | Glomerulonephritis, Membranous | Drug: Cyclophosphamide and steroids | Radboud University | NULL | Completed | 18 Years | 75 Years | Both | 29 | Phase 3 | Netherlands |
| 230 | EUCTR2016-003525-42-BE (EUCTR) | 30/10/2017 | A treatment study of ACH-0144471 in Patients with Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients with Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | biopsy-confirmed C3 Glomerulopathy (C3G) or idiopathic Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) and a low serum C3 level MedDRA version: 20.0;Level: PT;Classification code 10077827;Term: C3 glomerulopathy;System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Achillion Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 10 | Phase 2 | Belgium;Australia;Netherlands | ||||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 231 | EUCTR2016-005141-23-DE (EUCTR) | 30/05/2018 | Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) | A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) | Focal segmental glomerulosclerosis (FSGS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Sparsentan/Over-encapsulated Sparsentan tablet Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: SPARSENTAN Trade Name: Irbesartan tablets (NDC# 43547-0374-03 and NDC 43547-374-09, approved in the USA) Generic tablets distributed by Solco Healthcare US, LLC Product Name: over-encapsulated Irbesartan Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN Trade Name: Irbesartan tablets Product Name: over-encapsulated Irbesartan Tablets INN or Proposed INN: Irbesartan Other descriptive name: IRBESARTAN Product Name: Sparsentan Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: SPARSENTAN | Retrophin, Inc. | NULL | NA | Female: yes Male: yes | 300 | Phase 3 | United States;Portugal;Taiwan;Estonia;Hong Kong;Spain;United Kingdom;Italy;France;Hungary;Czech Republic;Canada;Argentina;Poland;Belgium;Brazil;Croatia;Australia;Denmark;Germany;New Zealand;Sweden;Korea, Republic of | |||
| 232 | EUCTR2019-001734-34-DE (EUCTR) | 12/09/2019 | Efficacy and safety of LNP023 compared with rituximab in subjects with idiopathic membranous nephropathy. | A randomized, treatment open-label, dose-blinded, parallel group, three arm, proof-of-concept clinical trial to investigate the efficacy and safety of LNP023 compared with rituximab in the treatment of subjects with idiopathic membranous nephropathy. | Idiopathic Membranous nephropathy MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: LNP023 INN or Proposed INN: not yet established Other descriptive name: LNP023 HYDROCHLORIDE SALT Product Code: LNP023 INN or Proposed INN: not yet established Other descriptive name: LNP023 HYDROCHLORIDE SALT Product Code: LNP023 INN or Proposed INN: not yet established Other descriptive name: LNP023 HYDROCHLORIDE SALT Trade Name: MabThera 500 mg concentrate for solution for infusion INN or Proposed INN: RITUXIMAB Trade Name: MabThera 100 mg concentrate for solution for infusion INN or Proposed INN: RITUXIMAB | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 72 | Phase 2 | United States;France;Czech Republic;Argentina;Spain;Singapore;Russian Federation;Netherlands;Germany;United Kingdom;India | |||
| 233 | EUCTR2015-001039-18-Outside-EU/EEA (EUCTR) | 03/07/2015 | Trial on the therapeutic effect of Tacrolimus in combination with low dosage corticosteroids compared with high dosage corticosteroids only, in patients with minimal change necrotic syndrome | Open-Label, Randomized, Comparative, Multi-Center Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf [Cap.]®) in Combination With Low-Dose Corticosteroid Compared With High-Dose Corticosteroid Alone in Patients With Minimal-Change Nephrotic Syndrome (MCNS) - T_OPTIMUM study | Minimal change nephrotic syndrome;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Prograf INN or Proposed INN: TACROLIMUS Trade Name: Prograf INN or Proposed INN: TACROLIMUS Trade Name: Solondo INN or Proposed INN: PREDNISOLONE Other descriptive name: PREDNISOLONE Trade Name: Solondo INN or Proposed INN: PREDNISOLONE Other descriptive name: PREDNISOLONE | Astellas Pharma Korea, Inc. | NULL | NA | Female: yes Male: yes | 152 | Korea, Republic of | ||||
| 234 | EUCTR2015-005450-36-Outside-EU/EEA (EUCTR) | 01/08/2016 | Pilot to Evaluate the Safety and Efficacy of Abatacept in Adults and Children Over the Age of 6 With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) | A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms With Switchover, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome (Focal Segmental Glomerulosclerosis/ Minimal Change) | Rheumatoid Arthritis MedDRA version: 19.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Orencia Product Name: Abatacept Product Code: BMS-188667 INN or Proposed INN: ABATACEPT | Bristol-Myers Squibb Company | NULL | NA | Female: yes Male: yes | 100 | Phase 2 | United States |